Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An <italic>In Silico</italic> Approach Applied to Emerging Infectious Diseases</title><author><name sortKey="Shi, Jiandong" sort="Shi, Jiandong" uniqKey="Shi J" first="Jiandong" last="Shi">Jiandong Shi</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff003"><addr-line>Prenatal Diagnosis Center, Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, Hebei, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Li, Sijin" sort="Li, Sijin" uniqKey="Li S" first="Sijin" last="Li">Sijin Li</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sun, Jing" sort="Sun, Jing" uniqKey="Sun J" first="Jing" last="Sun">Jing Sun</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Teng, Yumei" sort="Teng, Yumei" uniqKey="Teng Y" first="Yumei" last="Teng">Yumei Teng</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Wu, Meini" sort="Wu, Meini" uniqKey="Wu M" first="Meini" last="Wu">Meini Wu</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Li, Jianfan" sort="Li, Jianfan" uniqKey="Li J" first="Jianfan" last="Li">Jianfan Li</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Li, Yanhan" sort="Li, Yanhan" uniqKey="Li Y" first="Yanhan" last="Li">Yanhan Li</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Hu, Ningzhu" sort="Hu, Ningzhu" uniqKey="Hu N" first="Ningzhu" last="Hu">Ningzhu Hu</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Wang, Haixuan" sort="Wang, Haixuan" uniqKey="Wang H" first="Haixuan" last="Wang">Haixuan Wang</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Hu, Yunzhang" sort="Hu, Yunzhang" uniqKey="Hu Y" first="Yunzhang" last="Hu">Yunzhang Hu</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26641892</idno><idno type="pmc">4671582</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671582</idno><idno type="RBID">PMC:4671582</idno><idno type="doi">10.1371/journal.pone.0144475</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">001015</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001015</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An <italic>In Silico</italic> Approach Applied to Emerging Infectious Diseases</title><author><name sortKey="Shi, Jiandong" sort="Shi, Jiandong" uniqKey="Shi J" first="Jiandong" last="Shi">Jiandong Shi</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff003"><addr-line>Prenatal Diagnosis Center, Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, Hebei, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Li, Sijin" sort="Li, Sijin" uniqKey="Li S" first="Sijin" last="Li">Sijin Li</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sun, Jing" sort="Sun, Jing" uniqKey="Sun J" first="Jing" last="Sun">Jing Sun</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Teng, Yumei" sort="Teng, Yumei" uniqKey="Teng Y" first="Yumei" last="Teng">Yumei Teng</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Wu, Meini" sort="Wu, Meini" uniqKey="Wu M" first="Meini" last="Wu">Meini Wu</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Li, Jianfan" sort="Li, Jianfan" uniqKey="Li J" first="Jianfan" last="Li">Jianfan Li</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Li, Yanhan" sort="Li, Yanhan" uniqKey="Li Y" first="Yanhan" last="Li">Yanhan Li</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Hu, Ningzhu" sort="Hu, Ningzhu" uniqKey="Hu N" first="Ningzhu" last="Hu">Ningzhu Hu</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Wang, Haixuan" sort="Wang, Haixuan" uniqKey="Wang H" first="Haixuan" last="Wang">Haixuan Wang</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author><author><name sortKey="Hu, Yunzhang" sort="Hu, Yunzhang" uniqKey="Hu Y" first="Yunzhang" last="Hu">Yunzhang Hu</name><affiliation><nlm:aff id="aff001"><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Middle East respiratory syndrome coronavirus (MERS-CoV) with pandemic potential is a major worldwide threat to public health. However, vaccine development for this pathogen lags behind as immunity associated with protection is currently largely unknown. In this study, an immunoinformatics-driven genome-wide screening strategy of vaccine targets was performed to thoroughly screen the vital and effective dominant immunogens against MERS-CoV. Conservancy and population coverage analysis of the epitopes were done by the Immune Epitope Database. The results showed that the nucleocapsid (N) protein of MERS-CoV might be a better protective immunogen with high conservancy and potential eliciting both neutralizing antibodies and T-cell responses compared with spike (S) protein. Further, the B-cell, helper T-cell and cytotoxic T lymphocyte (CTL) epitopes were screened and mapped to the N protein. A total of 15 linear and 10 conformal B-cell epitopes that may induce protective neutralizing antibodies were obtained. Additionally, a total of 71 peptides with 9-mer core sequence were identified as helper T-cell epitopes, and 34 peptides were identified as CTL epitopes. Based on the maximum HLA binding alleles, top 10 helper T-cell epitopes and CTL epitopes that may elicit protective cellular immune responses against MERS-CoV were selected as MERS vaccine candidates. Population coverage analysis showed that the putative helper T-cell epitopes and CTL epitopes could cover the vast majority of the population in 15 geographic regions considered where vaccine would be employed. The B- and T-cell stimulation potentials of the screened epitopes is to be further validated for their efficient use as vaccines against MERS-CoV. Collectively, this study provides novel vaccine target candidates and may prompt further development of vaccines against MERS-CoV and other emerging infectious diseases.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bermingham, A" uniqKey="Bermingham A">A Bermingham</name></author><author><name sortKey="Chand, Ma" uniqKey="Chand M">MA Chand</name></author><author><name sortKey="Brown, Cs" uniqKey="Brown C">CS Brown</name></author><author><name sortKey="Aarons, E" uniqKey="Aarons E">E Aarons</name></author><author><name sortKey="Tong, C" uniqKey="Tong C">C Tong</name></author><author><name sortKey="Langrish, C" uniqKey="Langrish C">C Langrish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, Am" uniqKey="Zaki A">AM Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S van Boheemen</name></author><author><name sortKey="Bestebroer, Tm" uniqKey="Bestebroer T">TM Bestebroer</name></author><author><name sortKey="Osterhaus, Ad" uniqKey="Osterhaus A">AD Osterhaus</name></author><author><name sortKey="Fouchier, Ra" uniqKey="Fouchier R">RA Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coleman, Cm" uniqKey="Coleman C">CM Coleman</name></author><author><name sortKey="Frieman, Mb" uniqKey="Frieman M">MB Frieman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ithete, Nl" uniqKey="Ithete N">NL Ithete</name></author><author><name sortKey="Stoffberg, S" uniqKey="Stoffberg S">S Stoffberg</name></author><author><name sortKey="Corman, Vm" uniqKey="Corman V">VM Corman</name></author><author><name sortKey="Cottontail, Vm" uniqKey="Cottontail V">VM Cottontail</name></author><author><name sortKey="Richards, Lr" uniqKey="Richards L">LR Richards</name></author><author><name sortKey="Schoeman, Mc" uniqKey="Schoeman M">MC Schoeman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Briese, T" uniqKey="Briese T">T Briese</name></author><author><name sortKey="Mishra, N" uniqKey="Mishra N">N Mishra</name></author><author><name sortKey="Jain, K" uniqKey="Jain K">K Jain</name></author><author><name sortKey="Zalmout, Is" uniqKey="Zalmout I">IS Zalmout</name></author><author><name sortKey="Jabado, Oj" uniqKey="Jabado O">OJ Jabado</name></author><author><name sortKey="Karesh, Wb" uniqKey="Karesh W">WB Karesh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mackay, Im" uniqKey="Mackay I">IM Mackay</name></author><author><name sortKey="Arden, Ke" uniqKey="Arden K">KE Arden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A Zumla</name></author><author><name sortKey="Hui, Ds" uniqKey="Hui D">DS Hui</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S Perlman</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Song, F" uniqKey="Song F">F Song</name></author><author><name sortKey="Fux, R" uniqKey="Fux R">R Fux</name></author><author><name sortKey="Provacia, Lb" uniqKey="Provacia L">LB Provacia</name></author><author><name sortKey="Volz, A" uniqKey="Volz A">A Volz</name></author><author><name sortKey="Eickmann, M" uniqKey="Eickmann M">M Eickmann</name></author><author><name sortKey="Becker, S" uniqKey="Becker S">S Becker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, L" uniqKey="Wang L">L Wang</name></author><author><name sortKey="Shi, W" uniqKey="Shi W">W Shi</name></author><author><name sortKey="Joyce, Mg" uniqKey="Joyce M">MG Joyce</name></author><author><name sortKey="Modjarrad, K" uniqKey="Modjarrad K">K Modjarrad</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Leung, K" uniqKey="Leung K">K Leung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guo, X" uniqKey="Guo X">X Guo</name></author><author><name sortKey="Deng, Y" uniqKey="Deng Y">Y Deng</name></author><author><name sortKey="Chen, H" uniqKey="Chen H">H Chen</name></author><author><name sortKey="Lan, J" uniqKey="Lan J">J Lan</name></author><author><name sortKey="Wang, W" uniqKey="Wang W">W Wang</name></author><author><name sortKey="Zou, X" uniqKey="Zou X">X Zou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G Zhao</name></author><author><name sortKey="Kou, Z" uniqKey="Kou Z">Z Kou</name></author><author><name sortKey="Ma, C" uniqKey="Ma C">C Ma</name></author><author><name sortKey="Sun, S" uniqKey="Sun S">S Sun</name></author><author><name sortKey="Poon, Vk" uniqKey="Poon V">VK Poon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, E" uniqKey="Kim E">E Kim</name></author><author><name sortKey="Okada, K" uniqKey="Okada K">K Okada</name></author><author><name sortKey="Kenniston, T" uniqKey="Kenniston T">T Kenniston</name></author><author><name sortKey="Raj, Vs" uniqKey="Raj V">VS Raj</name></author><author><name sortKey="Alhajri, Mm" uniqKey="Alhajri M">MM AlHajri</name></author><author><name sortKey="Farag, Ea" uniqKey="Farag E">EA Farag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tang, J" uniqKey="Tang J">J Tang</name></author><author><name sortKey="Zhang, N" uniqKey="Zhang N">N Zhang</name></author><author><name sortKey="Tao, X" uniqKey="Tao X">X Tao</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G Zhao</name></author><author><name sortKey="Guo, Y" uniqKey="Guo Y">Y Guo</name></author><author><name sortKey="Tseng, Ct" uniqKey="Tseng C">CT Tseng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Volz, A" uniqKey="Volz A">A Volz</name></author><author><name sortKey="Kupke, A" uniqKey="Kupke A">A Kupke</name></author><author><name sortKey="Song, F" uniqKey="Song F">F Song</name></author><author><name sortKey="Jany, S" uniqKey="Jany S">S Jany</name></author><author><name sortKey="Fux, R" uniqKey="Fux R">R Fux</name></author><author><name sortKey="Shams Eldin, H" uniqKey="Shams Eldin H">H Shams-Eldin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mou, H" uniqKey="Mou H">H Mou</name></author><author><name sortKey="Raj, Vs" uniqKey="Raj V">VS Raj</name></author><author><name sortKey="Van Kuppeveld, Fj" uniqKey="Van Kuppeveld F">FJ van Kuppeveld</name></author><author><name sortKey="Rottier, Pj" uniqKey="Rottier P">PJ Rottier</name></author><author><name sortKey="Haagmans, Bl" uniqKey="Haagmans B">BL Haagmans</name></author><author><name sortKey="Bosch, Bj" uniqKey="Bosch B">BJ Bosch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G Zhao</name></author><author><name sortKey="Kou, Z" uniqKey="Kou Z">Z Kou</name></author><author><name sortKey="Ma, C" uniqKey="Ma C">C Ma</name></author><author><name sortKey="Sun, S" uniqKey="Sun S">S Sun</name></author><author><name sortKey="Poon, Vk" uniqKey="Poon V">VK Poon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author><author><name sortKey="Kou, Z" uniqKey="Kou Z">Z Kou</name></author><author><name sortKey="Ma, C" uniqKey="Ma C">C Ma</name></author><author><name sortKey="Tao, X" uniqKey="Tao X">X Tao</name></author><author><name sortKey="Wang, L" uniqKey="Wang L">L Wang</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, N" uniqKey="Zhang N">N Zhang</name></author><author><name sortKey="Jiang, S" uniqKey="Jiang S">S Jiang</name></author><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Almazan, F" uniqKey="Almazan F">F Almazán</name></author><author><name sortKey="Dediego, Ml" uniqKey="Dediego M">ML DeDiego</name></author><author><name sortKey="Sola, I" uniqKey="Sola I">I Sola</name></author><author><name sortKey="Zu Iga, S" uniqKey="Zu Iga S">S Zuñiga</name></author><author><name sortKey="Nieto Torres, Jl" uniqKey="Nieto Torres J">JL Nieto-Torres</name></author><author><name sortKey="Marquez Jurado, S" uniqKey="Marquez Jurado S">S Marquez-Jurado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Purcell, Aw" uniqKey="Purcell A">AW Purcell</name></author><author><name sortKey="Mccluskey, J" uniqKey="Mccluskey J">J McCluskey</name></author><author><name sortKey="Rossjohn, J" uniqKey="Rossjohn J">J Rossjohn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Firbas, C" uniqKey="Firbas C">C Firbas</name></author><author><name sortKey="Jilma, B" uniqKey="Jilma B">B Jilma</name></author><author><name sortKey="Tauber, E" uniqKey="Tauber E">E Tauber</name></author><author><name sortKey="Buerger, V" uniqKey="Buerger V">V Buerger</name></author><author><name sortKey="Jelovcan, S" uniqKey="Jelovcan S">S Jelovcan</name></author><author><name sortKey="Lingnau, K" uniqKey="Lingnau K">K Lingnau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stanekova, Z" uniqKey="Stanekova Z">Z Staneková</name></author><author><name sortKey="Vare Kova, E" uniqKey="Vare Kova E">E Varečková</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, L" uniqKey="He L">L He</name></author><author><name sortKey="Cheng, Y" uniqKey="Cheng Y">Y Cheng</name></author><author><name sortKey="Kong, L" uniqKey="Kong L">L Kong</name></author><author><name sortKey="Azadnia, P" uniqKey="Azadnia P">P Azadnia</name></author><author><name sortKey="Giang, E" uniqKey="Giang E">E Giang</name></author><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sominskaya, I" uniqKey="Sominskaya I">I Sominskaya</name></author><author><name sortKey="Skrastina, D" uniqKey="Skrastina D">D Skrastina</name></author><author><name sortKey="Dislers, A" uniqKey="Dislers A">A Dislers</name></author><author><name sortKey="Vasiljev, D" uniqKey="Vasiljev D">D Vasiljev</name></author><author><name sortKey="Mihailova, M" uniqKey="Mihailova M">M Mihailova</name></author><author><name sortKey="Ose, V" uniqKey="Ose V">V Ose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Terry, Fe" uniqKey="Terry F">FE Terry</name></author><author><name sortKey="Moise, L" uniqKey="Moise L">L Moise</name></author><author><name sortKey="Martin, Rf" uniqKey="Martin R">RF Martin</name></author><author><name sortKey="Torres, M" uniqKey="Torres M">M Torres</name></author><author><name sortKey="Pilotte, N" uniqKey="Pilotte N">N Pilotte</name></author><author><name sortKey="Williams, Sa" uniqKey="Williams S">SA Williams</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Doytchinova, Ia" uniqKey="Doytchinova I">IA Doytchinova</name></author><author><name sortKey="Flower, Dr" uniqKey="Flower D">DR Flower</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilkins, Mr" uniqKey="Wilkins M">MR Wilkins</name></author><author><name sortKey="Gasteiger, E" uniqKey="Gasteiger E">E Gasteiger</name></author><author><name sortKey="Bairoch, A" uniqKey="Bairoch A">A Bairoch</name></author><author><name sortKey="Sanchez, Jc" uniqKey="Sanchez J">JC Sanchez</name></author><author><name sortKey="Williams, Kl" uniqKey="Williams K">KL Williams</name></author><author><name sortKey="Appel, Rd" uniqKey="Appel R">RD Appel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Combet, C" uniqKey="Combet C">C Combet</name></author><author><name sortKey="Blanchet, C" uniqKey="Blanchet C">C Blanchet</name></author><author><name sortKey="Geourjon, C" uniqKey="Geourjon C">C Geourjon</name></author><author><name sortKey="Deleage, G" uniqKey="Deleage G">G Deléage</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="K Llberg, M" uniqKey="K Llberg M">M Källberg</name></author><author><name sortKey="Margaryan, G" uniqKey="Margaryan G">G Margaryan</name></author><author><name sortKey="Wang, S" uniqKey="Wang S">S Wang</name></author><author><name sortKey="Ma, J" uniqKey="Ma J">J Ma</name></author><author><name sortKey="Xu, J" uniqKey="Xu J">J Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kolaskar, As" uniqKey="Kolaskar A">AS Kolaskar</name></author><author><name sortKey="Tongaonkar, Pc" uniqKey="Tongaonkar P">PC Tongaonkar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vihinen, M" uniqKey="Vihinen M">M Vihinen</name></author><author><name sortKey="Torkkila, E" uniqKey="Torkkila E">E Torkkila</name></author><author><name sortKey="Riikonen, P" uniqKey="Riikonen P">P Riikonen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Emini, Ea" uniqKey="Emini E">EA Emini</name></author><author><name sortKey="Hughes, Jv" uniqKey="Hughes J">JV Hughes</name></author><author><name sortKey="Perlow, Ds" uniqKey="Perlow D">DS Perlow</name></author><author><name sortKey="Boger, J" uniqKey="Boger J">J Boger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilson, Ja" uniqKey="Wilson J">JA Wilson</name></author><author><name sortKey="Hart, Mk" uniqKey="Hart M">MK Hart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karosiene, E" uniqKey="Karosiene E">E Karosiene</name></author><author><name sortKey="Rasmussen, M" uniqKey="Rasmussen M">M Rasmussen</name></author><author><name sortKey="Blicher, T" uniqKey="Blicher T">T Blicher</name></author><author><name sortKey="Lund, O" uniqKey="Lund O">O Lund</name></author><author><name sortKey="Buus, S" uniqKey="Buus S">S Buus</name></author><author><name sortKey="Nielsen, M" uniqKey="Nielsen M">M Nielsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Udaka, K" uniqKey="Udaka K">K Udaka</name></author><author><name sortKey="Mamitsuka, H" uniqKey="Mamitsuka H">H Mamitsuka</name></author><author><name sortKey="Zhu, S" uniqKey="Zhu S">S Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nielsen, M" uniqKey="Nielsen M">M Nielsen</name></author><author><name sortKey="Lundegaard, C" uniqKey="Lundegaard C">C Lundegaard</name></author><author><name sortKey="Blicher, T" uniqKey="Blicher T">T Blicher</name></author><author><name sortKey="Lamberth, K" uniqKey="Lamberth K">K Lamberth</name></author><author><name sortKey="Harndahl, M" uniqKey="Harndahl M">M Harndahl</name></author><author><name sortKey="Justesen, S" uniqKey="Justesen S">S Justesen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoof, I" uniqKey="Hoof I">I Hoof</name></author><author><name sortKey="Peters, B" uniqKey="Peters B">B Peters</name></author><author><name sortKey="Sidney, J" uniqKey="Sidney J">J Sidney</name></author><author><name sortKey="Pedersen, Le" uniqKey="Pedersen L">LE Pedersen</name></author><author><name sortKey="Sette, A" uniqKey="Sette A">A Sette</name></author><author><name sortKey="Lund, O" uniqKey="Lund O">O Lund</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Y" uniqKey="Kim Y">Y Kim</name></author><author><name sortKey="Ponomarenko, J" uniqKey="Ponomarenko J">J Ponomarenko</name></author><author><name sortKey="Zhu, Z" uniqKey="Zhu Z">Z Zhu</name></author><author><name sortKey="Tamang, D" uniqKey="Tamang D">D Tamang</name></author><author><name sortKey="Wang, P" uniqKey="Wang P">P Wang</name></author><author><name sortKey="Greenbaum, J" uniqKey="Greenbaum J">J Greenbaum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nielsen, M" uniqKey="Nielsen M">M Nielsen</name></author><author><name sortKey="Lundegaard, C" uniqKey="Lundegaard C">C Lundegaard</name></author><author><name sortKey="Worning, P" uniqKey="Worning P">P Worning</name></author><author><name sortKey="Lauem Ller, Sl" uniqKey="Lauem Ller S">SL Lauemøller</name></author><author><name sortKey="Lamberth, K" uniqKey="Lamberth K">K Lamberth</name></author><author><name sortKey="Buus, S" uniqKey="Buus S">S Buus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lundegaard, C" uniqKey="Lundegaard C">C Lundegaard</name></author><author><name sortKey="Lamberth, K" uniqKey="Lamberth K">K Lamberth</name></author><author><name sortKey="Harndahl, M" uniqKey="Harndahl M">M Harndahl</name></author><author><name sortKey="Buus, S" uniqKey="Buus S">S Buus</name></author><author><name sortKey="Lund, O" uniqKey="Lund O">O Lund</name></author><author><name sortKey="Nielsen, M" uniqKey="Nielsen M">M Nielsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peters, B" uniqKey="Peters B">B Peters</name></author><author><name sortKey="Sette, A" uniqKey="Sette A">A Sette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sidney, J" uniqKey="Sidney J">J Sidney</name></author><author><name sortKey="Assarsson, E" uniqKey="Assarsson E">E Assarsson</name></author><author><name sortKey="Moore, C" uniqKey="Moore C">C Moore</name></author><author><name sortKey="Ngo, S" uniqKey="Ngo S">S Ngo</name></author><author><name sortKey="Pinilla, C" uniqKey="Pinilla C">C Pinilla</name></author><author><name sortKey="Sette, A" uniqKey="Sette A">A Sette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Calis, Jj" uniqKey="Calis J">JJ Calis</name></author><author><name sortKey="Maybeno, M" uniqKey="Maybeno M">M Maybeno</name></author><author><name sortKey="Greenbaum, Ja" uniqKey="Greenbaum J">JA Greenbaum</name></author><author><name sortKey="Weiskopf, D" uniqKey="Weiskopf D">D Weiskopf</name></author><author><name sortKey="De Silva, Ad" uniqKey="De Silva A">AD De Silva</name></author><author><name sortKey="Sette, A" uniqKey="Sette A">A Sette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bui, Hh" uniqKey="Bui H">HH Bui</name></author><author><name sortKey="Sidney, J" uniqKey="Sidney J">J Sidney</name></author><author><name sortKey="Li, W" uniqKey="Li W">W Li</name></author><author><name sortKey="Fusseder, N" uniqKey="Fusseder N">N Fusseder</name></author><author><name sortKey="Sette, A" uniqKey="Sette A">A Sette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muh, Hc" uniqKey="Muh H">HC Muh</name></author><author><name sortKey="Tong, Jc" uniqKey="Tong J">JC Tong</name></author><author><name sortKey="Tammi, Mt" uniqKey="Tammi M">MT Tammi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bui, Hh" uniqKey="Bui H">HH Bui</name></author><author><name sortKey="Sidney, J" uniqKey="Sidney J">J Sidney</name></author><author><name sortKey="Dinh, K" uniqKey="Dinh K">K Dinh</name></author><author><name sortKey="Southwood, S" uniqKey="Southwood S">S Southwood</name></author><author><name sortKey="Newman, Mj" uniqKey="Newman M">MJ Newman</name></author><author><name sortKey="Sette, A" uniqKey="Sette A">A Sette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Le, Tm" uniqKey="Le T">TM Le</name></author><author><name sortKey="Wong, Hh" uniqKey="Wong H">HH Wong</name></author><author><name sortKey="Tay, Fp" uniqKey="Tay F">FP Tay</name></author><author><name sortKey="Fang, S" uniqKey="Fang S">S Fang</name></author><author><name sortKey="Keng, Ct" uniqKey="Keng C">CT Keng</name></author><author><name sortKey="Tan, Yj" uniqKey="Tan Y">YJ Tan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, N" uniqKey="Wang N">N Wang</name></author><author><name sortKey="Shi, X" uniqKey="Shi X">X Shi</name></author><author><name sortKey="Jiang, L" uniqKey="Jiang L">L Jiang</name></author><author><name sortKey="Zhang, S" uniqKey="Zhang S">S Zhang</name></author><author><name sortKey="Wang, D" uniqKey="Wang D">D Wang</name></author><author><name sortKey="Tong, P" uniqKey="Tong P">P Tong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zheng, N" uniqKey="Zheng N">N Zheng</name></author><author><name sortKey="Xia, R" uniqKey="Xia R">R Xia</name></author><author><name sortKey="Yang, C" uniqKey="Yang C">C Yang</name></author><author><name sortKey="Yin, B" uniqKey="Yin B">B Yin</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Duan, C" uniqKey="Duan C">C Duan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ma, C" uniqKey="Ma C">C Ma</name></author><author><name sortKey="Yao, K" uniqKey="Yao K">K Yao</name></author><author><name sortKey="Zhou, F" uniqKey="Zhou F">F Zhou</name></author><author><name sortKey="Zhu, M" uniqKey="Zhu M">M Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hu, H" uniqKey="Hu H">H Hu</name></author><author><name sortKey="Tao, L" uniqKey="Tao L">L Tao</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author><author><name sortKey="Yang, J" uniqKey="Yang J">J Yang</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dutta, Nk" uniqKey="Dutta N">NK Dutta</name></author><author><name sortKey="Mazumdar, K" uniqKey="Mazumdar K">K Mazumdar</name></author><author><name sortKey="Lee, Bh" uniqKey="Lee B">BH Lee</name></author><author><name sortKey="Baek, Mw" uniqKey="Baek M">MW Baek</name></author><author><name sortKey="Kim, Dj" uniqKey="Kim D">DJ Kim</name></author><author><name sortKey="Na, Yr" uniqKey="Na Y">YR Na</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Sj" uniqKey="Liu S">SJ Liu</name></author><author><name sortKey="Leng, Ch" uniqKey="Leng C">CH Leng</name></author><author><name sortKey="Lien, Sp" uniqKey="Lien S">SP Lien</name></author><author><name sortKey="Chi, Hy" uniqKey="Chi H">HY Chi</name></author><author><name sortKey="Huang, Cy" uniqKey="Huang C">CY Huang</name></author><author><name sortKey="Lin, Cl" uniqKey="Lin C">CL Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name></author><author><name sortKey="Huang, Q" uniqKey="Huang Q">Q Huang</name></author><author><name sortKey="Wang, W" uniqKey="Wang W">W Wang</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Lv, P" uniqKey="Lv P">P Lv</name></author><author><name sortKey="Gao, Xm" uniqKey="Gao X">XM Gao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, M" uniqKey="Zhou M">M Zhou</name></author><author><name sortKey="Xu, D" uniqKey="Xu D">D Xu</name></author><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Li, H" uniqKey="Li H">H Li</name></author><author><name sortKey="Shan, M" uniqKey="Shan M">M Shan</name></author><author><name sortKey="Tang, J" uniqKey="Tang J">J Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Han, Z" uniqKey="Han Z">Z Han</name></author><author><name sortKey="Zhao, F" uniqKey="Zhao F">F Zhao</name></author><author><name sortKey="Shao, Y" uniqKey="Shao Y">Y Shao</name></author><author><name sortKey="Liu, X" uniqKey="Liu X">X Liu</name></author><author><name sortKey="Kong, X" uniqKey="Kong X">X Kong</name></author><author><name sortKey="Song, Y" uniqKey="Song Y">Y Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gupta, V" uniqKey="Gupta V">V Gupta</name></author><author><name sortKey="Tabiin, Tm" uniqKey="Tabiin T">TM Tabiin</name></author><author><name sortKey="Sun, K" uniqKey="Sun K">K Sun</name></author><author><name sortKey="Chandrasekaran, A" uniqKey="Chandrasekaran A">A Chandrasekaran</name></author><author><name sortKey="Anwar, A" uniqKey="Anwar A">A Anwar</name></author><author><name sortKey="Yang, K" uniqKey="Yang K">K Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Dq" uniqKey="Liu D">DQ Liu</name></author><author><name sortKey="Ge, Jw" uniqKey="Ge J">JW Ge</name></author><author><name sortKey="Qiao, Xy" uniqKey="Qiao X">XY Qiao</name></author><author><name sortKey="Jiang, Yp" uniqKey="Jiang Y">YP Jiang</name></author><author><name sortKey="Liu, Sm" uniqKey="Liu S">SM Liu</name></author><author><name sortKey="Li, Yj" uniqKey="Li Y">YJ Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilson, Ja" uniqKey="Wilson J">JA Wilson</name></author><author><name sortKey="Hart, Mk" uniqKey="Hart M">MK Hart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, X" uniqKey="Gao X">X Gao</name></author><author><name sortKey="Zhou, H" uniqKey="Zhou H">H Zhou</name></author><author><name sortKey="Wu, C" uniqKey="Wu C">C Wu</name></author><author><name sortKey="Xiao, Y" uniqKey="Xiao Y">Y Xiao</name></author><author><name sortKey="Ren, L" uniqKey="Ren L">L Ren</name></author><author><name sortKey="Paranhos Baccala, G" uniqKey="Paranhos Baccala G">G Paranhos-Baccalà</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Esser, Mt" uniqKey="Esser M">MT Esser</name></author><author><name sortKey="Marchese, Rd" uniqKey="Marchese R">RD Marchese</name></author><author><name sortKey="Kierstead, Ls" uniqKey="Kierstead L">LS Kierstead</name></author><author><name sortKey="Tussey, Lg" uniqKey="Tussey L">LG Tussey</name></author><author><name sortKey="Wang, F" uniqKey="Wang F">F Wang</name></author><author><name sortKey="Chirmule, N" uniqKey="Chirmule N">N Chirmule</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maenaka, K" uniqKey="Maenaka K">K Maenaka</name></author><author><name sortKey="Jones, Ey" uniqKey="Jones E">EY Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stern, Lj" uniqKey="Stern L">LJ Stern</name></author><author><name sortKey="Wiley, Dc" uniqKey="Wiley D">DC Wiley</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26641892</article-id><article-id pub-id-type="pmc">4671582</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0144475</article-id><article-id pub-id-type="publisher-id">PONE-D-15-41720</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An <italic>In Silico</italic> Approach Applied to Emerging Infectious Diseases</article-title><alt-title alt-title-type="running-head">Vaccine Target Screening against Pathogenic MERS-CoV</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shi</surname><given-names>Jiandong</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Sijin</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Teng</surname><given-names>Yumei</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Meini</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jianfan</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanhan</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Ningzhu</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haixuan</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yunzhang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Yunnan Provincial Key Laboratory of Arbo Infectious Disease Control Research (Preparing), Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Prenatal Diagnosis Center, Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, Hebei, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ray</surname><given-names>Ranjit</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>Saint Louis University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: JDS JZ YZH. Performed the experiments: JDS JZ SJL YMT JS MNW JFL YHL. Analyzed the data: JDS JZ. Contributed reagents/materials/analysis tools: NZH HXW. Wrote the paper: JDS.</p></fn><corresp id="cor001">* E-mail: <email>huyunzhangym@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>12</issue><elocation-id>e0144475</elocation-id><history><date date-type="received"><day>1</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>© 2015 Shi et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Shi et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0144475.pdf"></self-uri><abstract><p>Middle East respiratory syndrome coronavirus (MERS-CoV) with pandemic potential is a major worldwide threat to public health. However, vaccine development for this pathogen lags behind as immunity associated with protection is currently largely unknown. In this study, an immunoinformatics-driven genome-wide screening strategy of vaccine targets was performed to thoroughly screen the vital and effective dominant immunogens against MERS-CoV. Conservancy and population coverage analysis of the epitopes were done by the Immune Epitope Database. The results showed that the nucleocapsid (N) protein of MERS-CoV might be a better protective immunogen with high conservancy and potential eliciting both neutralizing antibodies and T-cell responses compared with spike (S) protein. Further, the B-cell, helper T-cell and cytotoxic T lymphocyte (CTL) epitopes were screened and mapped to the N protein. A total of 15 linear and 10 conformal B-cell epitopes that may induce protective neutralizing antibodies were obtained. Additionally, a total of 71 peptides with 9-mer core sequence were identified as helper T-cell epitopes, and 34 peptides were identified as CTL epitopes. Based on the maximum HLA binding alleles, top 10 helper T-cell epitopes and CTL epitopes that may elicit protective cellular immune responses against MERS-CoV were selected as MERS vaccine candidates. Population coverage analysis showed that the putative helper T-cell epitopes and CTL epitopes could cover the vast majority of the population in 15 geographic regions considered where vaccine would be employed. The B- and T-cell stimulation potentials of the screened epitopes is to be further validated for their efficient use as vaccines against MERS-CoV. Collectively, this study provides novel vaccine target candidates and may prompt further development of vaccines against MERS-CoV and other emerging infectious diseases.</p></abstract><funding-group><funding-statement>This research was supported by grant from the Applied and Fundamental Research program of Yunnan Province (Grant No. 2013FA025 and 2013BC011), which were received by Yunzhang Hu and Ningzhu Hu. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"></fig-count><table-count count="6"></table-count><page-count count="16"></page-count></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Middle East respiratory syndrome (MERS) is a newly emerging acute respiratory system infectious disease, which is characterised by acute pneumonia, respiratory failure, and renal failure and caused by MERS-coronavirus (MERS-CoV) [<xref rid="pone.0144475.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0144475.ref002" ref-type="bibr">2</xref>]. MERS-CoV was first isolated and identified in Saudi Arabia in 2012 as a new member in the lineage C of the genus <italic>Betacoronavirus</italic>, and is a zoonotic virus that is transmitted from bats to camels, and then to humans [<xref rid="pone.0144475.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0144475.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0144475.ref005" ref-type="bibr">5</xref>]. The genome of MERS-CoV is a non-segmented positive-sense, single-stranded RNA (ssRNA) of approximately 30 kb encoding 11 proteins. They include two replicase polyproteins (open reading frames 1ab and 1a); four structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins; and five nonstructural proteins (open reading frames 3, 4a, 4b, 5, and 8b) [<xref rid="pone.0144475.ref006" ref-type="bibr">6</xref>]. MERS-CoV can be transmitted from person-to-person and has as high as 40% mortality [<xref rid="pone.0144475.ref007" ref-type="bibr">7</xref>]. As of June 26 2015, a total of 1356 cases including 484 related deaths have been reported to the World Health Organization [<xref rid="pone.0144475.ref008" ref-type="bibr">8</xref>]. No licensed vaccine or specific treatment is currently available.</p><p>As one of the most effective strategies to prevent virus infection, vaccination is considered to be indispensable especially in the absence of effective treatment drugs. The continuous increase of patients and a high mortality rate of MERS-CoV infection highlight the urgent need for safe and effective vaccines development. The majority of recent progresses focused on the viral S glycoprotein and receptor-binding domain (RBD) of S protein [<xref rid="pone.0144475.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0144475.ref019" ref-type="bibr">19</xref>], and showed that S protein-based or RBD-based subunit or vector vaccine that contain multiple neutralizing epitopes with high potentials to induce strong neutralizing antibodies against MERS-CoV infection; thus, it is considered to be a promising target for effective MERS vaccine design [<xref rid="pone.0144475.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0144475.ref019" ref-type="bibr">19</xref>]. Additionally, Almazan <italic>et al</italic>. constructed a full-length infectious cDNA clone of the MERS-CoV genome that lacked of E gene by reverse genetics approach to develop attenuated viruses as vaccine candidates [<xref rid="pone.0144475.ref020" ref-type="bibr">20</xref>]. Theoretically, nearly all viral proteins are potential immunogens and vaccine targets. Thus, in addition to the S protein, other viral proteins of the MERS-CoV might be effective immunogen targets of MERS vaccine. However, few studies have analyzed or tested the possibility of other viral proteins of MERS-CoV as vaccine targets. More importantly, T-cell-based cellular immunity is essential for cleaning MERS-CoV infection, yet the vaccine against the S protein mainly elicits neutralizing antibody response. Further, the high mutation rate of the S protein may result in the escape of neutralizing antibodies against MERS-CoV. Therefore, a highly conserved target that elicit both neutralizing antibody and cellular immunity against MERS-CoV is essential for an effective vaccine development.</p><p>Epitopes are also known as the antigenic determinant, which represents the minimal immunogenic region of a protein antigen and precisely elicit a specific immune responses [<xref rid="pone.0144475.ref021" ref-type="bibr">21</xref>]. Numerous studies show that epitope-based vaccines could effectively elicit protective immune responses against diverse pathogens, such as human immunodeficiency virus, influenza virus, hepatitis B virus, and hepatitis C virus [<xref rid="pone.0144475.ref022" ref-type="bibr">22</xref>–<xref rid="pone.0144475.ref025" ref-type="bibr">25</xref>]. Nevertheless, for emerging highly pathogenic pathogens, like MERS-CoV, H5N1, and H7N9, although their genome sequences are available in GenBank database, their immunity associated with protection is currently largely unknown. These gaps in understanding immune protection make developing vaccines against these highly pathogenic viruses more difficult and challenging [<xref rid="pone.0144475.ref026" ref-type="bibr">26</xref>]. Therefore, an immunoinformatics-driven approach to thoroughly screen the dominant immunogens based on available genome sequences data of pathogens is essential and promising for effective vaccine design of emerging infectious diseases [<xref rid="pone.0144475.ref026" ref-type="bibr">26</xref>].</p><p>In this study, based on newly available genome sequence data of MERS-CoV, numerous epitope vaccine candidates that could elicit protective humoral and cellular immune responses were obtained by immunoinformatics-driven vaccine target screening strategy. These results provided new vaccine epitope candidates for MERS vaccine development, and indicated that immunoinformatic-driven immunogen screening is a promising strategy to accelerate vaccine development of the emerging highly pathogenic pathogens.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Protein sequence retrieval</title><p>The entire viral proteome sequences of all MERS-CoV isolates that include structural proteins spike protein (S), envelope protein (E), membrane protein (M), nucleocapsid protein (N), and non-structural proteins ORF3, ORF4a, ORF4b, ORF5 and ORF8b, and two replicase polyproteins ORF1ab and ORF1a, were retrieved from the National Center for Biotechnology Information database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</ext-link>) and used as an input for various bioinformatics tools for antigenicity assessment, secondary structure and 3D model prediction, and epitope prediction. These sequences come from different geographic regions such as Saudi Arabia, England, Qatar, Spain, Germany, Jordan, and Korea with time ranges from 2012 to 2015.</p></sec><sec id="sec004"><title>Antigenic protein screening and structure analysis</title><p>Antigenicity refers to the ability of antigen that can be recognized by the immune system. Hence, to find the best potential candidate antigen, the VaxiJen v2.0 server [<xref rid="pone.0144475.ref027" ref-type="bibr">27</xref>] (<ext-link ext-link-type="uri" xlink:href="http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html">http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html</ext-link>) was used for analyzing whole protein antigenicity and determined the most potent antigenic protein. The VaxiJen is a web server, that was developed by Dr. Doytchinova IA and Dr. Flower DR, from Faculty of Pharmacy, Medical University of Sofia, for prediction of protective antigens, tumor antigens and subunit vaccines, with prediction accuracy of 70% to 89% for the discrimination between antigens and non-antigens [<xref rid="pone.0144475.ref027" ref-type="bibr">27</xref>]. In this study, virus was chosen as the target organism with default parameter. A single antigenic protein with the highest antigenicity score was selected as vaccine candidate for further analysis. Antigenicity is closely related to the secondary and tertiary structure of the protein; hence, to determine the antigenicity and function of the target protein, the secondary structure of target protein that included solvent accessibility, transmembrane helices, globular regions, and coiled coil regions were predicted using the ExPASy’s secondary structure prediction server ProtParam [<xref rid="pone.0144475.ref028" ref-type="bibr">28</xref>] (<ext-link ext-link-type="uri" xlink:href="http://web.expasy.org/protparam/">http://web.expasy.org/protparam/</ext-link>) and a self-optimized prediction method for alignment (SOPMA) [<xref rid="pone.0144475.ref029" ref-type="bibr">29</xref>] (<ext-link ext-link-type="uri" xlink:href="https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html">https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html</ext-link>) with default parameter. ProtParam is a tool which allows the computation of various parameters including the molecular weight, theoretical pI, amino acid composition, atomic composition, extinction coefficient, estimated half-life, instability index, aliphatic index and grand average of hydropathicity (GRAVY) for a given protein. The SOPMA method correctly predicts 69.5% of the secondary structure α-helix, β-sheet and coil [<xref rid="pone.0144475.ref029" ref-type="bibr">29</xref>]. The RaptorX web server [<xref rid="pone.0144475.ref030" ref-type="bibr">30</xref>] (<ext-link ext-link-type="uri" xlink:href="http://raptorx.uchicago.edu/">http://raptorx.uchicago.edu/</ext-link>) was used to predict the three-dimensional (3D) structure and binding residues of the chosen protein.</p></sec><sec id="sec005"><title>B-cell epitope prediction</title><p>The method of Kolaskar and Tongaonkar [<xref rid="pone.0144475.ref031" ref-type="bibr">31</xref>] at the Immune Epitope Database (IEDB) (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/bcell/">http://tools.immuneepitope.org/bcell/</ext-link>) was applied to predict linear B-cell epitopes. The Kolaskar and Tongaonkar method has been applied to a large number of proteins to predict B-cell epitopes by the developers. Their results showed that the method can predict epitopes with about 75% accuracy; hence, it is better than most of the known methods [<xref rid="pone.0144475.ref031" ref-type="bibr">31</xref>]. Further, the properties of the B-cell epitopes also include the flexibility, surface accessibility and hydrophilicity; hence, they were predicted by the Karplus and Schulz flexibility prediction [<xref rid="pone.0144475.ref032" ref-type="bibr">32</xref>] and Emini surface accessibility prediction [<xref rid="pone.0144475.ref033" ref-type="bibr">33</xref>] with a threshold of 1.0 respectively, of the IEDB. Conformational B-cell epitopes were predicted by ElliPro (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/ellipro/">http://tools.immuneepitope.org/ellipro/</ext-link>) [<xref rid="pone.0144475.ref034" ref-type="bibr">34</xref>] with the minimum score value set at 0.7 while the maximum distance selected as 6 Å. The ElliPro allows the prediction and visualization of B-cell epitopes in a given protein sequence or structure. The test for ElliPro on a benchmark dataset of discontinuous epitopes inferred from 3D structures of antibody-antigen complexes has shown the best performance compared with six other structure-based epitope prediction methods [<xref rid="pone.0144475.ref034" ref-type="bibr">34</xref>].</p></sec><sec id="sec006"><title>Helper T-cell epitope prediction</title><p>The NetMHCIIpan 3.0 server [<xref rid="pone.0144475.ref035" ref-type="bibr">35</xref>] (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/NetMHCIIpan/">http://www.cbs.dtu.dk/services/NetMHCIIpan/</ext-link>) was used to predict helper T-cell epitopes. Threshold for strong binding peptides (IC<sub>50</sub>) was set at 50 nM to determine the binding and interaction potentials of helper T-cell epitope peptide and major histocompatibility complex (MHC) class II allele. The NetMHCIIpan-3.0 is the first pan-specific helper T-cell epitope prediction method that covers all human leucocyte antigen (HLA) class II molecules including HLA-DR, HLA-DP, and HLA-DQ. It can predict peptide binding to any HLA class II molecule in a specified protein sequence [<xref rid="pone.0144475.ref034" ref-type="bibr">34</xref>]. The method was evaluated by the developers and shown a significant improvement over molecule-specific methods; hence, it is considered the most accurate MHC class II predictor [<xref rid="pone.0144475.ref036" ref-type="bibr">36</xref>]. Here, the top 10 epitopes with the maximum of binding HLA-DR alleles were selected as putative epitope candidates.</p></sec><sec id="sec007"><title>CTL epitopes prediction</title><p>The cytotoxic T lymphocyte (CTL) epitope prediction was made using the IEDB analysis resource NetMHCpan (version 2.8) tool [<xref rid="pone.0144475.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0144475.ref038" ref-type="bibr">38</xref>] and the Consensus tool [<xref rid="pone.0144475.ref039" ref-type="bibr">39</xref>] which combines predictions from ANN aka NetMHC (3.4) [<xref rid="pone.0144475.ref040" ref-type="bibr">40</xref>][<xref rid="pone.0144475.ref041" ref-type="bibr">41</xref>], SMM [<xref rid="pone.0144475.ref042" ref-type="bibr">42</xref>], and Comblib [<xref rid="pone.0144475.ref043" ref-type="bibr">43</xref>]. The NetMHCpan is a high-throughput computational method for genome- and HLA-wide prediction of peptide binding to HLA class I molecules, because it contains all HLA class I alleles. Hence, it can offer a truly global analysis for binding of the antigenetic peptide and HLA molecule and promote rational vaccine design [<xref rid="pone.0144475.ref037" ref-type="bibr">37</xref>]. The NetMHC is a prediction method with an average of 75–80% accuracy for peptides binding to HLA class I molecules. It has been employed widely to predict HLA-binding peptides in proteomes of various pathogens including SARS, Influenza and HIV [<xref rid="pone.0144475.ref041" ref-type="bibr">41</xref>]. The percentile rank threshold was set at 0.5. In this study, the top 10 epitopes with the maximum of binding HLA-A alleles were selected as putative epitope vaccine candidates. Further, except for a strong binding affinity, the peptides with strong immunogenicity are more likely to be CTL epitopes than those with weak immunogenicity. Hence, the IEDB immunogenicity prediction tool (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/immunogenicity/">http://tools.immuneepitope.org/immunogenicity/</ext-link>) was used to predict the immunogenicity of the candidate epitopes [<xref rid="pone.0144475.ref044" ref-type="bibr">44</xref>]. This tool predicts immunogenicity of a peptide-HLA (pHLA) complex based on the amino acid properties and their positions in the defined peptide.</p></sec><sec id="sec008"><title>Conservancy analysis</title><p>The epitope conservancy analysis tool (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/tools/conservancy/iedb_input">http://tools.immuneepitope.org/tools/conservancy/iedb_input</ext-link>) at the IEDB was applied for the epitope conservancy analysis [<xref rid="pone.0144475.ref045" ref-type="bibr">45</xref>]. The conservancy levels were obtained by searching for identities in the given protein sequence. This tool calculates the degree of conservancy of an epitope within a given protein sequence set at different degrees of sequence identity. The degree of conservancy is defined as the fraction of protein sequences containing the epitope at a given identity level.</p></sec><sec id="sec009"><title>Allergenicity assessment</title><p>The allergenicity of the epitopes was analyzed by the AllerHunter server [<xref rid="pone.0144475.ref046" ref-type="bibr">46</xref>] (<ext-link ext-link-type="uri" xlink:href="http://tiger.dbs.nus.edu.sg/AllerHunter">http://tiger.dbs.nus.edu.sg/AllerHunter</ext-link>). AllerHunter is a SVM-pairwise system for assessment of allergenicity and allergic cross-reactivity in proteins. It aims to predict allergens and non-allergens with high sensitivity and specificity, without compromising efficiency at classification of proteins with similar sequences to known allergens [<xref rid="pone.0144475.ref046" ref-type="bibr">46</xref>].</p></sec><sec id="sec010"><title>Population coverage prediction</title><p>Due to the MHC restriction of T cell response, the peptides with more different HLA binding specificities mean more population coverage in defined geographical regions where the peptide-based vaccine might be employed. The population coverage rate of individual epitope was calculated using the IEDB population coverage tool (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/tools/population/iedb_input">http://tools.immuneepitope.org/tools/population/iedb_input</ext-link>) [<xref rid="pone.0144475.ref047" ref-type="bibr">47</xref>].</p><p>Every epitope and its binding HLA alleles were added, and different geographic areas were also selected.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Antigenic protein identification and structure analysis</title><p>The selection of immunogen is the first step for vaccine design; hence, to obtain the most probable antigenic protein, the whole viral proteomes of all MERS-CoV isolates were retrieved and screened. A total of 99 MERS-CoV variants from different geographical regions with their entire proteomes were obtained (<xref rid="pone.0144475.s004" ref-type="supplementary-material">S1 Table</xref>). The antigenicity of each protein is indicated by the overall score produced by the specific protein sequence using the VaxiJen server. On the whole, the scores of the N protein and ORF8b protein of MERS-CoV were higher than the S, E, M, ORF3, ORF4a, ORF4b, ORF5, ORF1ab and ORF1a proteins. Moreover, the ORF8b protein with its Genbank ID: AIL23997.1 and the N protein with its Genbank ID: AGV08499.1 possessed the significantly highest antigenic scores of 0.8218 and 0.7749, respectively, among all the query proteins (<xref rid="pone.0144475.s004" ref-type="supplementary-material">S1 Table</xref>). However, the ORF8b protein would be rapidly degraded by proteasomes in the absence of the ORF8a protein, an accessory protein of ORF8b [<xref rid="pone.0144475.ref048" ref-type="bibr">48</xref>]. Thus, it was not an ideal antigen candidate although its high antigenic score. In this study, the N protein was chosen as a candidate immunogen and model protein to carry out epitope-based vaccine design. Further, the most probable antigenic protein was analyzed for its secondary structural characteristics, and the properties that included total length of 413 aa, molecular weight of 45048.2 Da, theoretical pI of 10.05, formula of C<sub>1965</sub>H<sub>3102</sub>N<sub>594</sub>O<sub>611</sub>S<sub>7</sub>, 70 alpha helixes, 66 extended strands, 32 beta turns, and 245 random coils are obtained and shown in <xref rid="pone.0144475.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0144475.g001" ref-type="fig">Fig 1</xref>. The grand average of the hydrophobicity rule (GRAVY) of the N protein linear sequence was predicted to be negative (-0.865). This indicated the property of the protein as hydrophilic in nature and most of the residues to be present on the surface. This means that more amino acids tend to be binding residues when interacted with other proteins. The 3D structure showed a maximum of 64% identity of the N protein of MERS-CoV with the best template protein PDB: 2ofzA (RNA Binding Domain of Sars Nucleocapsid Protein), and it is composed of two separate domains or pockets (<xref rid="pone.0144475.g002" ref-type="fig">Fig 2</xref>). Protein binding site prediction showed that a total of 12 binding residues including T40, V41, S42, Y44, T45, G46, R97, Y99, Y101, R138, A145 and S173 were mapped on the domain-1. And only 2 binding residues including G267 and L268 were mapped on the domain-2. Obviously, the domain-1 possessed the greater ability to interact with other proteins than the domain-2. This might be associated with distribution of the conformational epitopes on the N protein of MERS-CoV.</p><fig id="pone.0144475.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.g001</object-id><label>Fig 1</label><caption><title>Secondary structure plot of the highest antigenic nucleocapsid (N) protein of MERS-CoV.</title><p>Here, helix is indicated by blue, while extended strands, beta turns and random coils are indicated by red, green and yellow, respectively.</p></caption><graphic xlink:href="pone.0144475.g001"></graphic></fig><fig id="pone.0144475.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.g002</object-id><label>Fig 2</label><caption><title>A 3D model of the highest antigenic nucleocapsid (N) protein of MERS-CoV that were modeled by using RaptorX web server.</title></caption><graphic xlink:href="pone.0144475.g002"></graphic></fig><table-wrap id="pone.0144475.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.t001</object-id><label>Table 1</label><caption><title>Secondary structural characteristics of the highest antigenic N protein (Genbank ID: AGV08499.1) of MERS-CoV.</title></caption><alternatives><graphic id="pone.0144475.t001g" xlink:href="pone.0144475.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Criteria</th><th align="center" rowspan="1" colspan="1">Assessment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of Amino Acids</td><td align="left" rowspan="1" colspan="1">413</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecular Weight</td><td align="left" rowspan="1" colspan="1">45048.2 Da</td></tr><tr><td align="left" rowspan="1" colspan="1">Theoretical pI</td><td align="left" rowspan="1" colspan="1">10.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of negatively charged residues (Asp + Glu)</td><td align="left" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of positively charged residues (Arg + Lys)</td><td align="left" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">Formula</td><td align="left" rowspan="1" colspan="1">C<sub>1965</sub>H<sub>3102</sub>N<sub>594</sub>O<sub>611</sub>S<sub>7</sub></td></tr><tr><td align="left" rowspan="1" colspan="1">Extinction coefficients</td><td align="left" rowspan="1" colspan="1">47900</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated half-life</td><td align="left" rowspan="1" colspan="1">30 hours (mammalian reticulocytes, in vitro)</td></tr><tr><td align="left" rowspan="1" colspan="1">Instability index</td><td align="left" rowspan="1" colspan="1">48.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Aliphatic index</td><td align="left" rowspan="1" colspan="1">56.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Grand average of hydropathicity (GRAVY)</td><td align="left" rowspan="1" colspan="1">-0.865</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec013"><title>Identification of B-cell epitopes</title><p>One of the key steps in epitope-driven vaccine design is the prediction and identification of the B-cell epitopes in target antigens. Thus, to obtain B-cell epitope candidates in the N protein of MERS-CoV, <italic>in silico</italic> identification of B-cell epitopes based on the IEDB database was performed. Based on the Kolaskar and Tongaonkar’s method of the IEDB, a total of 15 linear B-cell epitopes of the N protein of MERS-CoV were identified. The length of the epitopes ranged from 6 to 20 amino acids. These epitopes had 78–91% conservancy level among the specified N protein sequences. Notably, the epitopes <sup>4</sup>PAAPRAVSF<sup>12</sup> and <sup>324</sup>NPVYFLRYSGAIKL<sup>337</sup> were allergic to human; hence, they could not be vaccine candidates. Epitopes’ length, sequences, location, conservancy, and allergenicity are shown in <xref rid="pone.0144475.t002" ref-type="table">Table 2</xref>. Further, the results showed that the average antigenic prospensity value of the predicted epitopes was 0.993 with a minimum of 0.863 and a maximum of 1.182 (<xref rid="pone.0144475.s001" ref-type="supplementary-material">S1 Fig</xref>). Since surface accessibility and fragment flexibility are also key features for predicting B-cell epitopes. Thus, the surface accessibility and flexibility were analyzed based on methods of the IEDB. Results of the analysis of the surface accessibility of the predicted peptides showed that the maximum surface probability value was 6.971 at amino acid position from 363 to 368. The sequence of the hexapeptide is <sup>363</sup>KKEKKQ<sup>368</sup>, where 365E is the surface residue. The minimum value of surface probability is 0.074 for peptides <sup>205</sup>GIGAVG<sup>210</sup>, where 207G is the surface residue (<xref rid="pone.0144475.s002" ref-type="supplementary-material">S2 Fig</xref>). Likewise, results of the analysis of the flexibility of the predicted peptides showed that the maximum flexibility value was 1.160 at amino acid position from 170 to 176, and its sequence is <sup>167</sup>GNSQSSS<sup>173</sup>, where 170Q is the flexible residue. The minimum value of flexibility probability is 0.903 for peptides <sup>97</sup>RWYFYYT<sup>103</sup>, where 100F is the flexibility residue (<xref rid="pone.0144475.s003" ref-type="supplementary-material">S3 Fig</xref>). In addition, a total of 10 conformational B-cell epitopes having a Protrusion Index (PI) score value above 0.7 were obtained by the ElliPro. The highest probability of a conformational epitope was calculated at 97.9% (PI score: 0.979) and shown in <xref rid="pone.0144475.g003" ref-type="fig">Fig 3A</xref>. Residues involved in conformational epitopes, their location, number of residues, and scores are shown in <xref rid="pone.0144475.t003" ref-type="table">Table 3</xref>, whereas, their positions on 3D structures are shown in <xref rid="pone.0144475.g003" ref-type="fig">Fig 3A to 3J</xref>.</p><fig id="pone.0144475.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.g003</object-id><label>Fig 3</label><caption><title>3D representation of conformational epitopes (A to J) of the highest antigenic nucleocapsid (N) protein of MERS-CoV.</title><p>The epitopes are represented by yellow surface, and the bulk of the N protein is represented in grey sticks.</p></caption><graphic xlink:href="pone.0144475.g003"></graphic></fig><table-wrap id="pone.0144475.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.t002</object-id><label>Table 2</label><caption><title>Predicted linear B-cell epitopes of the N protein of MERS-CoV with their conservancy and allergenicity.</title></caption><alternatives><graphic id="pone.0144475.t002g" xlink:href="pone.0144475.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Epitope No.</th><th align="center" rowspan="1" colspan="1">Start</th><th align="center" rowspan="1" colspan="1">End</th><th align="center" rowspan="1" colspan="1">Sequence</th><th align="center" rowspan="1" colspan="1">Length</th><th align="center" rowspan="1" colspan="1">Conservancy (%)</th><th align="center" rowspan="1" colspan="1">Allergenicity</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">PAAPRAVSF</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">SWYTGL</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">HGKVPLTFP</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">GQGVPLN</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">KQLAPRWYFYY</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">EAALPFRAVKDGIVWVHED</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">144</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">SAIVTQF</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">172</td><td align="center" rowspan="1" colspan="1">180</td><td align="center" rowspan="1" colspan="1">SSRASSVSR</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">225</td><td align="center" rowspan="1" colspan="1">IGAVGGDLLYLDLLNRLQAL</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">230</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">VKQSQPKVITK</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">261</td><td align="center" rowspan="1" colspan="1">268</td><td align="center" rowspan="1" colspan="1">NMVQAFGL</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">296</td><td align="center" rowspan="1" colspan="1">304</td><td align="center" rowspan="1" colspan="1">IAELAPTAS</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">324</td><td align="center" rowspan="1" colspan="1">337</td><td align="center" rowspan="1" colspan="1">NPVYFLRYSGAIKL</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">347</td><td align="center" rowspan="1" colspan="1">353</td><td align="center" rowspan="1" colspan="1">WLELLEQ</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">399</td><td align="center" rowspan="1" colspan="1">405</td><td align="center" rowspan="1" colspan="1">RPSVQPG</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0144475.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.t003</object-id><label>Table 3</label><caption><title>Predicted conformational B-cell epitopes of the N protein of MERS-CoV.</title></caption><alternatives><graphic id="pone.0144475.t003g" xlink:href="pone.0144475.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Epitope No.</th><th align="left" rowspan="1" colspan="1">Residues and their positions</th><th align="left" rowspan="1" colspan="1">No. of Residues</th><th align="left" rowspan="1" colspan="1">Score</th><th align="left" rowspan="1" colspan="1">3D Structure</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">K346, W347, L348, E349</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0.979</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3A</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Y327, F328, L329, R330</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">0.893</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3B</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">L350, L351, E352, Q353, N354, I355, D356, A357, Y358, K359, T360, F361, P362, K363, K364, E365</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0.887</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3C</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y331, S332, G333, A334, I335, K336, L337, D338, P339, K340, N341, P342, N343, Y344, N345</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0.881</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3D</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">D320, D321, H322, G323,N324, P325, V326</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">0.867</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3E</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">H252, K253, R254, T255, S256, T257, K258, S259, F260, N261, M262, V263, Q264, A265, F266, G267, L268, R269, G270, P271, G272, D273, L274, Q275,G276, N277, F278, G279, D280, L281, Q282, L283, N284, K285, L286, G287, T288, E289, D290, P291, R292</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0.861</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3F</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">R399, P400, S401, V402, Q403, P404, G405, P406, M407, I408, D409, V410, N411, T412, D413</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">0.794</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3G</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">W293, P294, Q295, I296, A297, E298</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">0.778</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3H</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">F312, K313, L314, T315, H316, Q317, N318, N319</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">0.772</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3I</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">L299, A300, P301, T302, A303, S304, A305, F306, M307, G308, M309, S310, Q311</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">0.709</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0144475.g003" ref-type="fig">Fig 3J</xref></td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec014"><title>Identification of helper T-cell epitopes</title><p>Since MHC-II restricted CD4<sup>+</sup> T-cells activation is important for inducing and maintaining an efficient antibody response or CTL response, hence, the helper T-cell epitopes in the N protein of MERS-CoV were <italic>in silico</italic> identified. As a result, a total of 71 antigenic peptides with 9-mer core sequences in the N protein of MERS-CoV were identified to be helper T-cell epitopes using the NetMHCIIpan 3.0 server (<xref rid="pone.0144475.s005" ref-type="supplementary-material">S2 Table</xref>). They can bind a different large number of HLA-DR alleles with an IC<sub>50</sub> value less than 50nM, which indicated a very high binding affinity to HLA-DR molecules. Based on the fact that a good T-cell epitope should interact with as many HLA alleles as possible, the top 10 epitopes with the highest number of binding HLA-DR alleles were selected as putative helper T-cell epitope candidates (<xref rid="pone.0144475.t004" ref-type="table">Table 4</xref>). All of the 10 putative helper T-cell epitopes with numerous binding HLA-DR alleles tend to be good epitope candidates. Among them, the epitope <sup>329</sup>LRYSGAIKL<sup>337</sup> interacting with 357 HLA-DR alleles was the epitope possessing the maximum number of binding HLA-DR alleles. On the contrary, <sup>230</sup>VKQSQPKVI<sup>238</sup> interacting with 94 HLA-DR alleles is the epitope possessing the minimum number of binding HLA-DR alleles. Further, all selected putative epitopes were highly conserved with 89–91% conversancy level, and no epitope was found allergic to humans. Details of predicted putative helper T-cell epitopes along with their respective binding HLA-DR alleles are shown in <xref rid="pone.0144475.s005" ref-type="supplementary-material">S2 Table</xref>.</p><table-wrap id="pone.0144475.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.t004</object-id><label>Table 4</label><caption><title>Helper T-cell epitopes of the N protein of MERS-CoV selected on the basis of maximum HLA binding alleles.</title></caption><alternatives><graphic id="pone.0144475.t004g" xlink:href="pone.0144475.t004"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Epitope core sequence (9 -mer)</th><th align="center" rowspan="1" colspan="1">Position</th><th align="center" rowspan="1" colspan="1">No. of binding HLA-DR alleles</th><th align="center" rowspan="1" colspan="1">Conservancy (%)</th><th align="center" rowspan="1" colspan="1">Allergenicity</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">FNMVQAFGL</td><td align="center" rowspan="1" colspan="1">260–268</td><td align="center" rowspan="1" colspan="1">173</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">LRYSGAIKL</td><td align="center" rowspan="1" colspan="1">329–337</td><td align="center" rowspan="1" colspan="1">356</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">LQALESGKV</td><td align="center" rowspan="1" colspan="1">222–230</td><td align="center" rowspan="1" colspan="1">139</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">LNRLQALES</td><td align="center" rowspan="1" colspan="1">219–227</td><td align="center" rowspan="1" colspan="1">144</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">FMGMSQFKL</td><td align="center" rowspan="1" colspan="1">306–314</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">LYLDLLNRL</td><td align="center" rowspan="1" colspan="1">214–222</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">IKQLAPRWY</td><td align="center" rowspan="1" colspan="1">91–99</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">FLRYSGAIK</td><td align="center" rowspan="1" colspan="1">328–336</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">LLYLDLLNR</td><td align="center" rowspan="1" colspan="1">213–221</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">VKQSQPKVI</td><td align="center" rowspan="1" colspan="1">230–238</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec015"><title>Identification of CTL epitopes</title><p>As we all know, MHC-I restricted CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) plays a crucial role in controlling virus infection. Hence, identification of CTL epitopes is vital for understanding the principles of T cell activation and epitope-driven vaccine design. Herein, a total of 34 immunogenic peptides with 9-mer sequences in the N protein of MERS-CoV were identified to be CTL epitopes using the MHC-I binding predictions of the IEDB with recommended methods (<xref rid="pone.0144475.s006" ref-type="supplementary-material">S3 Table</xref>). They can bind a different large number of HLA-A alleles with a very high binding affinity. Top 10 epitopes binding the most HLA-A alleles were selected as putative CTL epitope candidates based on their more broad HLA coverage (<xref rid="pone.0144475.t005" ref-type="table">Table 5</xref>). Among them, the epitope <sup>92</sup>KQLAPRWYF<sup>100</sup> had the highest number of binding HLA-A alleles (138 alleles), followed by <sup>343</sup>NYNKWLELL<sup>351</sup> (128 alleles). Yet, the epitopes <sup>72</sup>AQNAGYWRR<sup>80</sup> (37 alleles) and <sup>387</sup>RVQGSITQR<sup>395</sup> (31 alleles) had the minimum number of binding HLA-A alleles. Most CTL epitope candidates with a positive score of immunogenicity showed a high potential to elicit strong CTL response. Further, these CTL epitope candidates were highly conserved with 85–91% conservancy level among available N protein sequences of MERS-CoV isolates, and no epitope was found allergic to humans. Details of predicted putative CTL epitopes along with their respective binding HLA-A alleles are shown in <xref rid="pone.0144475.s006" ref-type="supplementary-material">S3 Table</xref>.</p><table-wrap id="pone.0144475.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.t005</object-id><label>Table 5</label><caption><title>CTL epitopes of the N protein of MERS-CoV selected on the basis of maximum HLA binding alleles.</title></caption><alternatives><graphic id="pone.0144475.t005g" xlink:href="pone.0144475.t005"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Epitope sequence (9 -mer)</th><th align="center" rowspan="1" colspan="1">Position</th><th align="center" rowspan="1" colspan="1">No. of binding HLA-A alleles</th><th align="left" rowspan="1" colspan="1">Immunogenicity</th><th align="left" rowspan="1" colspan="1">Conservancy (%)</th><th align="left" rowspan="1" colspan="1">Allergenicity</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">AQNAGYWRR</td><td align="center" rowspan="1" colspan="1">72–80</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">0.28397</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">LAPRWYFYY</td><td align="center" rowspan="1" colspan="1">94–102</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">0.35734</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">NYNKWLELL</td><td align="center" rowspan="1" colspan="1">343–351</td><td align="center" rowspan="1" colspan="1">128</td><td align="center" rowspan="1" colspan="1">0.06418</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">KQLAPRWYF</td><td align="center" rowspan="1" colspan="1">92–100</td><td align="center" rowspan="1" colspan="1">138</td><td align="center" rowspan="1" colspan="1">0.25847</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">ELAPTASAF</td><td align="center" rowspan="1" colspan="1">298–306</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">-0.04059</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">NTVSWYTGL</td><td align="center" rowspan="1" colspan="1">39–47</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">0.11171</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">STPAQNAGY</td><td align="center" rowspan="1" colspan="1">69–77</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">-0.0303</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">QLAPRWYFY</td><td align="center" rowspan="1" colspan="1">93–101</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">0.32573</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">HGNPVYFLR</td><td align="center" rowspan="1" colspan="1">322–330</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">0.11578</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">RVQGSITQR</td><td align="center" rowspan="1" colspan="1">387–395</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">-0.07424</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">No</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec016"><title>Population coverage of the epitopes</title><p>HLA distribution varies among different ethnic groups and geographic regions around the world. Thus, population coverage must be taken into account when designing an effective vaccine to cover as much as possible populations. In this study, all indicated alleles in supplementary data were identified as optimum binders with the predicted epitopes and were used to determine the population coverage for these epitopes. The high population coverage was found for all putative helper T-cell epitopes and CTL epitopes in 15 specified geographic regions of the world (<xref rid="pone.0144475.t006" ref-type="table">Table 6</xref>). For helper T-cell epitopes, an excellent percentage of cumulative population coverage of the 10 epitopes was obtained in South Asia (98.68%), closely followed by Central Africa (98.51%), Southeast Asia (98.17%), West Africa (98.10%), East Africa (97.75%), Southwest Asia (97.45%), Oceania (96.78%), West Indies (96.57%), Northeast Asia (96.20%), Europe (95.77%), North Africa (95.05%), North America (94.81%), East Asia (93.89%), and South America (87.18%). And the lowest was in South Africa (62.18%). These results indicated most geographic regions of the world, where more than 90% of their population can be covered by all putative helper T-cell epitopes. For CTL epitopes, a moderate and acceptable percentage of cumulative population coverage of the 10 epitopes was obtained in Central Africa (59.49%), followed by East Asia (50.14%), Oceania (48.85%), Southwest Asia (48.21%), South Asia (47.21%), East Africa (42.51%), Southeast Asia (42.01%), West Africa (41.86%), South Africa (38.95%), North America (35.03%), North Africa (33.02%), South America (32.71%), Northeast Asia (32.47%), and West Indies (30.08%). And the lowest was in Europe (20.62%). These results indicated only partial regions of the world, such as Central Africa and East Asia, where approximately half of the population can be covered by all putative CTL epitopes. Overall, these results suggested that putative helper T-cell epitopes and CTL epitopes can specifically bind with the prevalent HLA molecules in the target population where the vaccine will be employed.</p><table-wrap id="pone.0144475.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0144475.t006</object-id><label>Table 6</label><caption><title>Population coverage rate (%) for all putative helper T-cell epitopes and CTL epitopes of the N protein of MERS-CoV.</title></caption><alternatives><graphic id="pone.0144475.t006g" xlink:href="pone.0144475.t006"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Population/Area</th><th colspan="2" align="center" rowspan="1">Population coverage (%)</th></tr><tr><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1">All putative helper T-cell epitopes</th><th align="center" rowspan="1" colspan="1">All putative CTL epitopes</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">East Asia</td><td align="center" rowspan="1" colspan="1">93.89</td><td align="center" rowspan="1" colspan="1">50.14</td></tr><tr><td align="center" rowspan="1" colspan="1">Northeast Asia</td><td align="center" rowspan="1" colspan="1">96.20</td><td align="center" rowspan="1" colspan="1">32.47</td></tr><tr><td align="center" rowspan="1" colspan="1">Sourth Asia</td><td align="center" rowspan="1" colspan="1">98.68</td><td align="center" rowspan="1" colspan="1">47.21</td></tr><tr><td align="center" rowspan="1" colspan="1">Southeast Asia</td><td align="center" rowspan="1" colspan="1">98.17</td><td align="center" rowspan="1" colspan="1">42.01</td></tr><tr><td align="center" rowspan="1" colspan="1">Southwest Asia</td><td align="center" rowspan="1" colspan="1">97.45</td><td align="center" rowspan="1" colspan="1">48.21</td></tr><tr><td align="center" rowspan="1" colspan="1">Europe</td><td align="center" rowspan="1" colspan="1">95.77</td><td align="center" rowspan="1" colspan="1">20.62</td></tr><tr><td align="center" rowspan="1" colspan="1">East Africa</td><td align="center" rowspan="1" colspan="1">97.75</td><td align="center" rowspan="1" colspan="1">42.51</td></tr><tr><td align="center" rowspan="1" colspan="1">West Africa</td><td align="center" rowspan="1" colspan="1">98.10</td><td align="center" rowspan="1" colspan="1">41.86</td></tr><tr><td align="center" rowspan="1" colspan="1">Central Africa</td><td align="center" rowspan="1" colspan="1">98.51</td><td align="center" rowspan="1" colspan="1">59.49</td></tr><tr><td align="center" rowspan="1" colspan="1">North Africa</td><td align="center" rowspan="1" colspan="1">95.05</td><td align="center" rowspan="1" colspan="1">33.02</td></tr><tr><td align="center" rowspan="1" colspan="1">South Africa</td><td align="center" rowspan="1" colspan="1">62.18</td><td align="center" rowspan="1" colspan="1">38.95</td></tr><tr><td align="center" rowspan="1" colspan="1">West Indies</td><td align="center" rowspan="1" colspan="1">96.57</td><td align="center" rowspan="1" colspan="1">30.08</td></tr><tr><td align="center" rowspan="1" colspan="1">North America</td><td align="center" rowspan="1" colspan="1">94.81</td><td align="center" rowspan="1" colspan="1">35.03</td></tr><tr><td align="center" rowspan="1" colspan="1">South America</td><td align="center" rowspan="1" colspan="1">87.18</td><td align="center" rowspan="1" colspan="1">32.71</td></tr><tr><td align="center" rowspan="1" colspan="1">Oceania</td><td align="center" rowspan="1" colspan="1">96.78</td><td align="center" rowspan="1" colspan="1">48.85</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>Emerging infectious pathogens such as MERS-CoV, H5N1, and H7N9 are highly pathogenic for humans. For these pathogens, immunity associated with protection remain largely unknown. Gaps in understanding the protective immunity against these pathogens make developing vaccines for newly emerging infectious diseases more difficult and challenging [<xref rid="pone.0144475.ref026" ref-type="bibr">26</xref>]. Thus, the genome-wide screening of vaccine targets based on newly available genome sequences data of pathogens is essential and urgent for developing efficiently vaccines against these newly emerging highly pathogenic pathogens.</p><p>This study aim to screen and investigate the most antigenic protein of the MERS-CoV and to find out the B- and T-cell epitopes that were mapped on the most antigenic protein by using a strategy namely genome-wide screening of vaccine epitopes. Based on advances in bioinformatics, the immunoinformatics approach could be an effective and essential strategy for vaccine development of emerging highly pathogenic pathogens. In this study, an immunoinformatics-driven approach was used to screen vital dominant immunogens against MERS-CoV. The results showed that the N protein was a better antigenic protein with the highest antigenic scores compared with other viral proteins in entire viral proteome. However, nearly all current studies of MERS vaccine focused on the S protein of MERS-CoV [<xref rid="pone.0144475.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0144475.ref019" ref-type="bibr">19</xref>], because the S protein mediated recognition of host cell DPP4 receptor for MRES-CoV and induced significant immune response [<xref rid="pone.0144475.ref049" ref-type="bibr">49</xref>]. In fact, not just the S protein, other MERS-CoV viral proteins might be effective MERS vaccine candidates. However, few studies have emphasized this possibility. Further, T-cell-based cellular immunity is essential for cleaning MERS-CoV infection, yet the vaccine against the S protein mainly elicit neutralizing antibody response. More importantly, high mutation rate of the S protein of MERS-CoV may cause escape of neutralizing antibodies against S protein. Therefore, an ideal target should be highly conserved that elicit both neutralizing antibody and cellular immunity against MERS-CoV, which is more essential for an effective MERS vaccine development. The N protein of human CoV is abundantly produced during infection and exhibits strong immunogenicity and conservancy, which can act as an ideal immunogen to elicit both cellular and humoral immune responses [<xref rid="pone.0144475.ref050" ref-type="bibr">50</xref>]. It is noteworthy that a large number of previous studies have shown the feasibility of the N protein as an immune target antigen or vaccine product [<xref rid="pone.0144475.ref051" ref-type="bibr">51</xref>–<xref rid="pone.0144475.ref060" ref-type="bibr">60</xref>]. Ma <italic>et al</italic>. demonstrated that a SARS-CoV vaccine based on the N gene that was expressed by DNA plasmid and adenovirus vector could induce detectable antibody and IFN-γ [<xref rid="pone.0144475.ref051" ref-type="bibr">51</xref>]. Similar studies of the DNA vaccine based on the SARS-CoV N gene have shown potential inducing specific humoral and cellular immunity in BALB/c mice [<xref rid="pone.0144475.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0144475.ref053" ref-type="bibr">53</xref>]. Moreover, multiple immunodominant B-cell epitopes, helper T-cell epitopes and CTL epitopes were mapped on the N protein of SARS-CoV [<xref rid="pone.0144475.ref054" ref-type="bibr">54</xref>–<xref rid="pone.0144475.ref058" ref-type="bibr">58</xref>]. Additionally, the antigenicity of the N protein from other viruses has been demonstrated [<xref rid="pone.0144475.ref059" ref-type="bibr">59</xref>,<xref rid="pone.0144475.ref060" ref-type="bibr">60</xref>]. And the antibodies against the N proteins of diverse human CoVs have been revealed by Gao <italic>et al</italic>. [<xref rid="pone.0144475.ref061" ref-type="bibr">61</xref>]. Based on these findings, it concludes that the N protein of MERS-CoV might be a putative and valuable immunogen for vaccine development. Further, the screened epitopes from the N protein in this study also may be some valuable epitope-based vaccine candidates for further <italic>in vitro</italic> and <italic>in vivo</italic> tests for their antigenic and immunogenetic potentials.</p><p>The purpose of vaccination is to induce immunity against specific pathogens by selectively stimulating antigen-specific B-cells or CTLs, and helper T-cells. Theoretically, a vaccine should contain two classes of antigenic epitopes: a helper T-cell epitope and a B-cell epitope or a CTL epitope. Based on a combination of these epitopes, the vaccine is able to either induce specific humoral or cellular immune against specific pathogens [<xref rid="pone.0144475.ref021" ref-type="bibr">21</xref>]. Therefore, the B-cell, CTL, and helper T-cell epitopes were screened systemically in the N protein of MERS-CoV to obtain putative epitope vaccine candidates. In this study, one B-cell epitope, <sup>108</sup>EAALPFRAVKDGIVWVHED<sup>126</sup>, showed a lower conservancy of 78% among different MERS-CoV isolates compared with other 14 epitopes, suggesting that it might be not an idea epitope candidate based on the fact that an epitope should be as conservative as possible to provide broader protection among different virus strains. In addition, various continuous and discontinuous B-cell epitopes were mapped on the N protein (<xref rid="pone.0144475.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0144475.g003" ref-type="fig">Fig 3</xref>). All discontinuous B-cell epitopes were located on the surface of the domain-2 of the N protein, showing the accessibility for the entered virus. Moreover, the diverse T-cell epitopes including helper T-cell epitopes and CTL epitopes were delineated by dissecting the N proteins (Tables <xref rid="pone.0144475.t004" ref-type="table">4</xref> and <xref rid="pone.0144475.t005" ref-type="table">5</xref>). Notably, neutralizing antibodies are not far enough to completely clean infectious pathogens. CTLs are needed because they play a central role in the generation of a protective immune response against diverse pathogen infection [<xref rid="pone.0144475.ref062" ref-type="bibr">62</xref>]. In this study, although the CTL epitope <sup>93</sup>QLAPRWYFY<sup>101</sup> showed the highest immunogenic score of 0.32573, it possessed the minimal HLA binding alleles among all predicted CTL epitopes. On the contrary, the epitope <sup>92</sup>KQLAPRWYF<sup>100</sup> had the maximum HLA binding alleles, but less immunogenic score of 0.25847. This inconsistency of immunological characteristics among different epitopes suggested that various parameters needed to be considered when screened epitopes. Helper T-cell epitopes are critical to the generation of vigorous humoral and CTL responses. However, the response to T-cell epitopes is restricted by HLA proteins. Moreover, HLA is highly polymorphic in diverse ethnic populations. Therefore, to induce broad immune responses in diverse ethnic genetically diverse human populations, the HLA specificity of T-cell epitopes must be considered first as a major criteria for screening of the epitopes [<xref rid="pone.0144475.ref063" ref-type="bibr">63</xref>,<xref rid="pone.0144475.ref064" ref-type="bibr">64</xref>]. Based on the above analysis, to get more population coverage, the epitope candidates should bind more HLA alleles. In this study, the 10 ten helper T-cell epitopes and CTL epitopes that bind the maximum number of HLA alleles were selected as putative vaccine candidates. Further analysis revealed that all putative helper T-cell and CTL epitopes have an ideal population coverage and may provide broad immune protection for different geographic regions around the world. Additionally, as an ideal epitope, it should be highly conserved among different MERS-CoV isolates. Thus, conservancy level should be determined for all putative epitope candidates. The epitopes from this study were highly conserved in designated MERS-CoV isolates, suggesting that they could be ideal epitope vaccine candidates to elicit protective neutralizing antibodies and cellular immune responses against MERS-CoV.</p></sec><sec sec-type="conclusions" id="sec018"><title>Conclusions</title><p>In conclusion, this study indicated that immunoinformatics-driven genome-wide screening of vaccine targets of emerging highly pathogenic pathogens is a promising strategy to accelerate their vaccine development. Based on this strategy, the B-cell epitopes, helper T-cell epitopes and CTL epitopes in the N protein of MERS-CoV were mapped and selected as putative MERS vaccine candidates. However, the B-and T-cell stimulation potentials of the screened epitopes are needed to be tested by <italic>in vitro</italic> and <italic>in vivo</italic> experiments along with this <italic>in silico</italic> study for their efficient use as vaccines against MERS-CoV. The present study provides new and valuable epitope candidates and prompts the future vaccine development of MERS and other emerging infectious diseases.</p></sec><sec sec-type="supplementary-material" id="sec019"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0144475.s001"><label>S1 Fig</label><caption><title>Kolaskar and Tongaonkar’s antigenicity prediction of the N protein of MERS-CoV.</title><p>X-axis represents the amino acids, whereas Y-axis represents the antigenic propensity. Average antigenic score was 0.993. Area displayed by the threshold line is considered as potential B-cell antigenic regions.</p><p>(PDF)</p></caption><media xlink:href="pone.0144475.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0144475.s002"><label>S2 Fig</label><caption><title>Emini surface accessibility prediction of the N protein of MERS-CoV.</title><p>X-axis represents the amino acids, whereas Y-axis represents accessible propensity. Average antigenic score was 1.000. Area displayed by the threshold line is considered as potential B-cell accessible regions.</p><p>(PDF)</p></caption><media xlink:href="pone.0144475.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0144475.s003"><label>S3 Fig</label><caption><title>Karplus and schulz flexibility prediction of the N protein of MERS-CoV.</title><p>X-axis represents the amino acids, whereas Y-axis represents flexible propensity. Average antigenic score was 1.028. Area displayed by the threshold line is considered as potential B-cell flexible regions.</p><p>(PDF)</p></caption><media xlink:href="pone.0144475.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0144475.s004"><label>S1 Table</label><caption><title>Antigenic scores of the entire proteomes of all MERS-CoV isolates.</title><p>(XLS)</p></caption><media xlink:href="pone.0144475.s004.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0144475.s005"><label>S2 Table</label><caption><title>9-mer peptide core sequences in the N protein of MERS-CoV are predicted to be helper T-cell epitopes using the NetMHCIIpan 3.0 web server.</title><p>(DOC)</p></caption><media xlink:href="pone.0144475.s005.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0144475.s006"><label>S3 Table</label><caption><title>9-mer peptide sequences in the N protein of MERS-CoV are predicted to be CTL epitopes using the IEDB MHC-I binding prediction web server.</title><p>(DOC)</p></caption><media xlink:href="pone.0144475.s006.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0144475.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Bermingham</surname><given-names>A</given-names></name>, <name><surname>Chand</surname><given-names>MA</given-names></name>, <name><surname>Brown</surname><given-names>CS</given-names></name>, <name><surname>Aarons</surname><given-names>E</given-names></name>, <name><surname>Tong</surname><given-names>C</given-names></name>, <name><surname>Langrish</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012</article-title>. <source>Euro Surveill</source>. <year>2012</year>;<volume>17</volume>(<issue>40</issue>):<fpage>20290</fpage><pub-id pub-id-type="pmid">23078800</pub-id></mixed-citation></ref><ref id="pone.0144475.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Zaki</surname><given-names>AM</given-names></name>, <name><surname>van Boheemen</surname><given-names>S</given-names></name>, <name><surname>Bestebroer</surname><given-names>TM</given-names></name>, <name><surname>Osterhaus</surname><given-names>AD</given-names></name>, <name><surname>Fouchier</surname><given-names>RA</given-names></name>. <article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title>. <source>N Engl J Med</source>. <year>2012</year>; <volume>367</volume>(<issue>19</issue>):<fpage>1814</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1211721</pub-id><pub-id pub-id-type="pmid">23075143</pub-id></mixed-citation></ref><ref id="pone.0144475.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Coleman</surname><given-names>CM</given-names></name>, <name><surname>Frieman</surname><given-names>MB</given-names></name>. <article-title>Coronaviruses: important emerging human pathogens</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>(<issue>10</issue>):<fpage>5209</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03488-13</pub-id><pub-id pub-id-type="pmid">24600003</pub-id></mixed-citation></ref><ref id="pone.0144475.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Ithete</surname><given-names>NL</given-names></name>, <name><surname>Stoffberg</surname><given-names>S</given-names></name>, <name><surname>Corman</surname><given-names>VM</given-names></name>, <name><surname>Cottontail</surname><given-names>VM</given-names></name>, <name><surname>Richards</surname><given-names>LR</given-names></name>, <name><surname>Schoeman</surname><given-names>MC</given-names></name>, <etal>et al</etal><article-title>Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa</article-title>. <source>Emerg Infect Dis</source>. <year>2013</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1697</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3201/eid1910.130946</pub-id><pub-id pub-id-type="pmid">24050621</pub-id></mixed-citation></ref><ref id="pone.0144475.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Briese</surname><given-names>T</given-names></name>, <name><surname>Mishra</surname><given-names>N</given-names></name>, <name><surname>Jain</surname><given-names>K</given-names></name>, <name><surname>Zalmout</surname><given-names>IS</given-names></name>, <name><surname>Jabado</surname><given-names>OJ</given-names></name>, <name><surname>Karesh</surname><given-names>WB</given-names></name>, <etal>et al</etal><article-title>Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia</article-title>. <source>MBio</source>. <year>2014</year>;<volume>5</volume>(<issue>3</issue>):<fpage>e01146</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.01146-14</pub-id><pub-id pub-id-type="pmid">24781747</pub-id></mixed-citation></ref><ref id="pone.0144475.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Mackay</surname><given-names>IM</given-names></name>, <name><surname>Arden</surname><given-names>KE</given-names></name>. <article-title>Middle East respiratory syndrome: An emerging coronavirus infection tracked by the crowd</article-title>. <source>Virus Res</source>. <year>2015</year>;<volume>202</volume>:<fpage>60</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2015.01.021</pub-id><pub-id pub-id-type="pmid">25656066</pub-id></mixed-citation></ref><ref id="pone.0144475.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Zumla</surname><given-names>A</given-names></name>, <name><surname>Hui</surname><given-names>DS</given-names></name>, <name><surname>Perlman</surname><given-names>S</given-names></name>. <article-title>Middle East respiratory syndrome</article-title>. <source>Lancet</source>. <year>2015</year>; <volume>386</volume>(<issue>9997</issue>): <fpage>995</fpage>–<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60454-8</pub-id><pub-id pub-id-type="pmid">26049252</pub-id></mixed-citation></ref><ref id="pone.0144475.ref008"><label>8</label><mixed-citation publication-type="other">World Health Organization. Middle East respiratory syndrome coronavirus (MERSCoV)–Republic of Korea. 26 June 2015. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/26-june-2015-mers-korea/en/">http://www.who.int/csr/don/26-june-2015-mers-korea/en/</ext-link>. Accessed 2015 Jul 16.</mixed-citation></ref><ref id="pone.0144475.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>F</given-names></name>, <name><surname>Fux</surname><given-names>R</given-names></name>, <name><surname>Provacia</surname><given-names>LB</given-names></name>, <name><surname>Volz</surname><given-names>A</given-names></name>, <name><surname>Eickmann</surname><given-names>M</given-names></name>, <name><surname>Becker</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>21</issue>):<fpage>11950</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01672-13</pub-id><pub-id pub-id-type="pmid">23986586</pub-id></mixed-citation></ref><ref id="pone.0144475.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Shi</surname><given-names>W</given-names></name>, <name><surname>Joyce</surname><given-names>MG</given-names></name>, <name><surname>Modjarrad</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Leung</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title>. <source>Nat Commun</source>. <year>2015</year>; <volume>6</volume>:<fpage>7712</fpage><pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id></mixed-citation></ref><ref id="pone.0144475.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>X</given-names></name>, <name><surname>Deng</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Lan</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Zou</surname><given-names>X</given-names></name>, <etal>et al</etal><article-title>Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus</article-title>. <source>Immunology</source>. <year>2015</year>;<volume>145</volume>(<issue>4</issue>):<fpage>476</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12462</pub-id><pub-id pub-id-type="pmid">25762305</pub-id></mixed-citation></ref><ref id="pone.0144475.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>L</given-names></name>, <name><surname>Zhao</surname><given-names>G</given-names></name>, <name><surname>Kou</surname><given-names>Z</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Sun</surname><given-names>S</given-names></name>, <name><surname>Poon</surname><given-names>VK</given-names></name>, <etal>et al</etal><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>17</issue>):<fpage>9939</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01048-13</pub-id><pub-id pub-id-type="pmid">23824801</pub-id></mixed-citation></ref><ref id="pone.0144475.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>E</given-names></name>, <name><surname>Okada</surname><given-names>K</given-names></name>, <name><surname>Kenniston</surname><given-names>T</given-names></name>, <name><surname>Raj</surname><given-names>VS</given-names></name>, <name><surname>AlHajri</surname><given-names>MM</given-names></name>, <name><surname>Farag</surname><given-names>EA</given-names></name>, <etal>et al</etal><article-title>Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>45</issue>):<fpage>5975</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.058</pub-id><pub-id pub-id-type="pmid">25192975</pub-id></mixed-citation></ref><ref id="pone.0144475.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>N</given-names></name>, <name><surname>Tao</surname><given-names>X</given-names></name>, <name><surname>Zhao</surname><given-names>G</given-names></name>, <name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Tseng</surname><given-names>CT</given-names></name>, <etal>et al</etal><article-title>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus</article-title>. <source>Hum Vaccin Immunother</source>. <year>2015</year>;<volume>11</volume>(<issue>5</issue>):<fpage>1244</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmid">25874632</pub-id></mixed-citation></ref><ref id="pone.0144475.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Volz</surname><given-names>A</given-names></name>, <name><surname>Kupke</surname><given-names>A</given-names></name>, <name><surname>Song</surname><given-names>F</given-names></name>, <name><surname>Jany</surname><given-names>S</given-names></name>, <name><surname>Fux</surname><given-names>R</given-names></name>, <name><surname>Shams-Eldin</surname><given-names>H</given-names></name>, <etal>et al</etal><article-title>Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein</article-title>. <source>J Virol</source>. <year>2015</year>;<volume>89</volume>(<issue>16</issue>):<fpage>8651</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00614-15</pub-id><pub-id pub-id-type="pmid">26018172</pub-id></mixed-citation></ref><ref id="pone.0144475.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Mou</surname><given-names>H</given-names></name>, <name><surname>Raj</surname><given-names>VS</given-names></name>, <name><surname>van Kuppeveld</surname><given-names>FJ</given-names></name>, <name><surname>Rottier</surname><given-names>PJ</given-names></name>, <name><surname>Haagmans</surname><given-names>BL</given-names></name>, <name><surname>Bosch</surname><given-names>BJ</given-names></name>. <article-title>The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>16</issue>):<fpage>9379</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01277-13</pub-id><pub-id pub-id-type="pmid">23785207</pub-id></mixed-citation></ref><ref id="pone.0144475.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>L</given-names></name>, <name><surname>Zhao</surname><given-names>G</given-names></name>, <name><surname>Kou</surname><given-names>Z</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Sun</surname><given-names>S</given-names></name>, <name><surname>Poon</surname><given-names>VK</given-names></name>, <etal>et al</etal><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>17</issue>):<fpage>9939</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01048-13</pub-id><pub-id pub-id-type="pmid">23824801</pub-id></mixed-citation></ref><ref id="pone.0144475.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>L</given-names></name>, <name><surname>Kou</surname><given-names>Z</given-names></name>, <name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Tao</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zhao</surname><given-names>G</given-names></name>, <etal>et al</etal><article-title>A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>12</issue>):<fpage>e81587</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0081587</pub-id><pub-id pub-id-type="pmid">24324708</pub-id></mixed-citation></ref><ref id="pone.0144475.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>N</given-names></name>, <name><surname>Jiang</surname><given-names>S</given-names></name>, <name><surname>Du</surname><given-names>L</given-names></name>. <article-title>Current advancements and potential strategies in the development of MERS-CoV vaccines</article-title>. <source>Expert Rev Vaccines</source>. <year>2014</year>;<volume>13</volume>(<issue>6</issue>):<fpage>761</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2014.912134</pub-id><pub-id pub-id-type="pmid">24766432</pub-id></mixed-citation></ref><ref id="pone.0144475.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Almazán</surname><given-names>F</given-names></name>, <name><surname>DeDiego</surname><given-names>ML</given-names></name>, <name><surname>Sola</surname><given-names>I</given-names></name>, <name><surname>Zuñiga</surname><given-names>S</given-names></name>, <name><surname>Nieto-Torres</surname><given-names>JL</given-names></name>, <name><surname>Marquez-Jurado</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate</article-title>. <source>MBio</source>. <year>2013</year>;<volume>4</volume>(<issue>5</issue>):<fpage>e00650</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00650-13</pub-id><pub-id pub-id-type="pmid">24023385</pub-id></mixed-citation></ref><ref id="pone.0144475.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Purcell</surname><given-names>AW</given-names></name>, <name><surname>McCluskey</surname><given-names>J</given-names></name>, <name><surname>Rossjohn</surname><given-names>J</given-names></name>. <article-title>More than one reason to rethink the use of peptides in vaccine design</article-title>. <source>Nat Rev Drug Discov</source>. <year>2007</year>;<volume>6</volume>(<issue>5</issue>):<fpage>404</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="pmid">17473845</pub-id></mixed-citation></ref><ref id="pone.0144475.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Firbas</surname><given-names>C</given-names></name>, <name><surname>Jilma</surname><given-names>B</given-names></name>, <name><surname>Tauber</surname><given-names>E</given-names></name>, <name><surname>Buerger</surname><given-names>V</given-names></name>, <name><surname>Jelovcan</surname><given-names>S</given-names></name>, <name><surname>Lingnau</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects</article-title>. <source>Vaccine</source>. <year>2006</year>; <volume>24</volume>(<issue>20</issue>):<fpage>4343</fpage>–<lpage>53</lpage>.
<pub-id pub-id-type="pmid">16581161</pub-id></mixed-citation></ref><ref id="pone.0144475.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Staneková</surname><given-names>Z</given-names></name>, <name><surname>Varečková</surname><given-names>E</given-names></name>. <article-title>Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development</article-title>. <source>Virol J</source>. <year>2010</year>;<volume>7</volume>:<fpage>351</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-7-351</pub-id><pub-id pub-id-type="pmid">21118546</pub-id></mixed-citation></ref><ref id="pone.0144475.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>L</given-names></name>, <name><surname>Cheng</surname><given-names>Y</given-names></name>, <name><surname>Kong</surname><given-names>L</given-names></name>, <name><surname>Azadnia</surname><given-names>P</given-names></name>, <name><surname>Giang</surname><given-names>E</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<fpage>12501</fpage><pub-id pub-id-type="doi">10.1038/srep12501</pub-id><pub-id pub-id-type="pmid">26238798</pub-id></mixed-citation></ref><ref id="pone.0144475.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Sominskaya</surname><given-names>I</given-names></name>, <name><surname>Skrastina</surname><given-names>D</given-names></name>, <name><surname>Dislers</surname><given-names>A</given-names></name>, <name><surname>Vasiljev</surname><given-names>D</given-names></name>, <name><surname>Mihailova</surname><given-names>M</given-names></name>, <name><surname>Ose</surname><given-names>V</given-names></name>, <etal>et al</etal><article-title>Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes</article-title>. <source>Clin Vaccine Immunol</source>. <year>2010</year>;<volume>17</volume>(<issue>6</issue>):<fpage>1027</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00468-09</pub-id><pub-id pub-id-type="pmid">20410327</pub-id></mixed-citation></ref><ref id="pone.0144475.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Terry</surname><given-names>FE</given-names></name>, <name><surname>Moise</surname><given-names>L</given-names></name>, <name><surname>Martin</surname><given-names>RF</given-names></name>, <name><surname>Torres</surname><given-names>M</given-names></name>, <name><surname>Pilotte</surname><given-names>N</given-names></name>, <name><surname>Williams</surname><given-names>SA</given-names></name>, <etal>et al</etal><article-title>Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases</article-title>. <source>Expert Rev Vaccines</source>. <year>2015</year>;<volume>14</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2015.955478</pub-id><pub-id pub-id-type="pmid">25193104</pub-id></mixed-citation></ref><ref id="pone.0144475.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Doytchinova</surname><given-names>IA</given-names></name>, <name><surname>Flower</surname><given-names>DR</given-names></name>. <article-title>VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines</article-title>. <source>BMC Bioinformatics</source>. <year>2007</year>;<volume>8</volume>:<fpage>4</fpage><pub-id pub-id-type="pmid">17207271</pub-id></mixed-citation></ref><ref id="pone.0144475.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Wilkins</surname><given-names>MR</given-names></name>, <name><surname>Gasteiger</surname><given-names>E</given-names></name>, <name><surname>Bairoch</surname><given-names>A</given-names></name>, <name><surname>Sanchez</surname><given-names>JC</given-names></name>, <name><surname>Williams</surname><given-names>KL</given-names></name>, <name><surname>Appel</surname><given-names>RD</given-names></name>, <etal>et al</etal><article-title>Protein identification and analysis tools in the ExPASy server</article-title>. <source>Methods Mol Biol</source>. <year>1999</year>;<volume>112</volume>:<fpage>531</fpage>–<lpage>52</lpage>.
<pub-id pub-id-type="pmid">10027275</pub-id></mixed-citation></ref><ref id="pone.0144475.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Combet</surname><given-names>C</given-names></name>, <name><surname>Blanchet</surname><given-names>C</given-names></name>, <name><surname>Geourjon</surname><given-names>C</given-names></name>, <name><surname>Deléage</surname><given-names>G</given-names></name>. <article-title>NPS@: network protein sequence analysis</article-title>. <source>Trends Biochem Sci</source>. <year>2000</year>;<volume>25</volume>(<issue>3</issue>):<fpage>147</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="pmid">10694887</pub-id></mixed-citation></ref><ref id="pone.0144475.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Källberg</surname><given-names>M</given-names></name>, <name><surname>Margaryan</surname><given-names>G</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>. <article-title>RaptorX server: a resource for template-based protein structure modeling</article-title>. <source>Methods Mol Biol</source>. <year>2014</year>;<volume>1137</volume>:<fpage>17</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-0366-5_2</pub-id><pub-id pub-id-type="pmid">24573471</pub-id></mixed-citation></ref><ref id="pone.0144475.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Kolaskar</surname><given-names>AS</given-names></name>, <name><surname>Tongaonkar</surname><given-names>PC</given-names></name>. <article-title>A semi-empirical method for prediction of antigenic determinants on protein antigens</article-title>. <source>FEBS Lett</source>. <year>1990</year>;<volume>276</volume>(<issue>1–2</issue>):<fpage>172</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="pmid">1702393</pub-id></mixed-citation></ref><ref id="pone.0144475.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Vihinen</surname><given-names>M</given-names></name>, <name><surname>Torkkila</surname><given-names>E</given-names></name>, <name><surname>Riikonen</surname><given-names>P</given-names></name>. <article-title>Accuracy of protein flexibility predictions</article-title>. <source>Proteins</source>. <year>1994</year>; <volume>19</volume>(<issue>2</issue>):<fpage>141</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="pmid">8090708</pub-id></mixed-citation></ref><ref id="pone.0144475.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Emini</surname><given-names>EA</given-names></name>, <name><surname>Hughes</surname><given-names>JV</given-names></name>, <name><surname>Perlow</surname><given-names>DS</given-names></name>, <name><surname>Boger</surname><given-names>J</given-names></name>. <article-title>Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide</article-title>. <source>J Virol</source>. <year>1985</year>;<volume>55</volume>(<issue>3</issue>):<fpage>836</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="pmid">2991600</pub-id></mixed-citation></ref><ref id="pone.0144475.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>JA</given-names></name>, <name><surname>Hart</surname><given-names>MK</given-names></name>. <article-title>Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein</article-title>. <source>J Virol</source>. <year>2001</year>;<volume>75</volume>(<issue>6</issue>):<fpage>2660</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="pmid">11222689</pub-id></mixed-citation></ref><ref id="pone.0144475.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Karosiene</surname><given-names>E</given-names></name>, <name><surname>Rasmussen</surname><given-names>M</given-names></name>, <name><surname>Blicher</surname><given-names>T</given-names></name>, <name><surname>Lund</surname><given-names>O</given-names></name>, <name><surname>Buus</surname><given-names>S</given-names></name>, <name><surname>Nielsen</surname><given-names>M</given-names></name>. <article-title>NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ</article-title>. <source>Immunogenetics</source>. <year>2013</year>;<volume>65</volume>(<issue>10</issue>):<fpage>711</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00251-013-0720-y</pub-id><pub-id pub-id-type="pmid">23900783</pub-id></mixed-citation></ref><ref id="pone.0144475.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Udaka</surname><given-names>K</given-names></name>, <name><surname>Mamitsuka</surname><given-names>H</given-names></name>, <name><surname>Zhu</surname><given-names>S</given-names></name>. <article-title>Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools</article-title>. <source>Brief Bioinform</source>. <year>2012</year>;<volume>13</volume>(<issue>3</issue>):<fpage>350</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbr060</pub-id><pub-id pub-id-type="pmid">21949215</pub-id></mixed-citation></ref><ref id="pone.0144475.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>M</given-names></name>, <name><surname>Lundegaard</surname><given-names>C</given-names></name>, <name><surname>Blicher</surname><given-names>T</given-names></name>, <name><surname>Lamberth</surname><given-names>K</given-names></name>, <name><surname>Harndahl</surname><given-names>M</given-names></name>, <name><surname>Justesen</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence</article-title>. <source>PLoS One</source>. <year>2007</year>;<volume>2</volume>(<issue>8</issue>):<fpage>e796</fpage><pub-id pub-id-type="pmid">17726526</pub-id></mixed-citation></ref><ref id="pone.0144475.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Hoof</surname><given-names>I</given-names></name>, <name><surname>Peters</surname><given-names>B</given-names></name>, <name><surname>Sidney</surname><given-names>J</given-names></name>, <name><surname>Pedersen</surname><given-names>LE</given-names></name>, <name><surname>Sette</surname><given-names>A</given-names></name>, <name><surname>Lund</surname><given-names>O</given-names></name>, <etal>et al</etal><article-title>NetMHCpan, a method for MHC class I binding prediction beyond humans</article-title>. <source>Immunogenetics</source>. <year>2009</year>;<volume>61</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/s00251-008-0341-z</pub-id><pub-id pub-id-type="pmid">19002680</pub-id></mixed-citation></ref><ref id="pone.0144475.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>Y</given-names></name>, <name><surname>Ponomarenko</surname><given-names>J</given-names></name>, <name><surname>Zhu</surname><given-names>Z</given-names></name>, <name><surname>Tamang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Greenbaum</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Immune epitope database analysis resource</article-title>. <source>Nucleic Acids Res</source>. <year>2012</year>; <volume>40</volume>(Web Server issue):<fpage>W525</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks438</pub-id><pub-id pub-id-type="pmid">22610854</pub-id></mixed-citation></ref><ref id="pone.0144475.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>M</given-names></name>, <name><surname>Lundegaard</surname><given-names>C</given-names></name>, <name><surname>Worning</surname><given-names>P</given-names></name>, <name><surname>Lauemøller</surname><given-names>SL</given-names></name>, <name><surname>Lamberth</surname><given-names>K</given-names></name>, <name><surname>Buus</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Reliable prediction of T-cell epitopes using neural networks with novel sequence representations</article-title>. <source>Protein Sci</source>. <year>2003</year>;<volume>12</volume>(<issue>5</issue>):<fpage>1007</fpage>–<lpage>17</lpage>.:
<pub-id pub-id-type="pmid">12717023</pub-id></mixed-citation></ref><ref id="pone.0144475.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Lundegaard</surname><given-names>C</given-names></name>, <name><surname>Lamberth</surname><given-names>K</given-names></name>, <name><surname>Harndahl</surname><given-names>M</given-names></name>, <name><surname>Buus</surname><given-names>S</given-names></name>, <name><surname>Lund</surname><given-names>O</given-names></name>, <name><surname>Nielsen</surname><given-names>M</given-names></name>. <article-title>NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11</article-title>. <source>Nucleic Acids Res</source>. <year>2008</year>;<volume>36</volume>(Web Server issue):<fpage>W509</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn202</pub-id><pub-id pub-id-type="pmid">18463140</pub-id></mixed-citation></ref><ref id="pone.0144475.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>B</given-names></name>, <name><surname>Sette</surname><given-names>A</given-names></name>. <article-title>Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method</article-title>. <source>BMC Bioinformatics</source>. <year>2005</year>;<volume>6</volume>:<fpage>132</fpage><pub-id pub-id-type="pmid">15927070</pub-id></mixed-citation></ref><ref id="pone.0144475.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Sidney</surname><given-names>J</given-names></name>, <name><surname>Assarsson</surname><given-names>E</given-names></name>, <name><surname>Moore</surname><given-names>C</given-names></name>, <name><surname>Ngo</surname><given-names>S</given-names></name>, <name><surname>Pinilla</surname><given-names>C</given-names></name>, <name><surname>Sette</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries</article-title>. <source>Immunome Res</source>. <year>2008</year>;<volume>4</volume>:<fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1745-7580-4-2</pub-id><pub-id pub-id-type="pmid">18221540</pub-id></mixed-citation></ref><ref id="pone.0144475.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Calis</surname><given-names>JJ</given-names></name>, <name><surname>Maybeno</surname><given-names>M</given-names></name>, <name><surname>Greenbaum</surname><given-names>JA</given-names></name>, <name><surname>Weiskopf</surname><given-names>D</given-names></name>, <name><surname>De Silva</surname><given-names>AD</given-names></name>, <name><surname>Sette</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Properties of MHC class I presented peptides that enhance immunogenicity</article-title>. <source>PLoS Comput Biol</source>. <year>2013</year>;<volume>9</volume>(<issue>10</issue>):<fpage>e1003266</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003266</pub-id><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/24204222">http://www.ncbi.nlm.nih.gov/pubmed/24204222</ext-link><pub-id pub-id-type="pmid">24204222</pub-id></mixed-citation></ref><ref id="pone.0144475.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Bui</surname><given-names>HH</given-names></name>, <name><surname>Sidney</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Fusseder</surname><given-names>N</given-names></name>, <name><surname>Sette</surname><given-names>A</given-names></name>. <article-title>Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines</article-title>. <source>BMC Bioinformatics</source>. <year>2007</year>;<volume>8</volume>:<fpage>361</fpage><pub-id pub-id-type="pmid">17897458</pub-id></mixed-citation></ref><ref id="pone.0144475.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Muh</surname><given-names>HC</given-names></name>, <name><surname>Tong</surname><given-names>JC</given-names></name>, <name><surname>Tammi</surname><given-names>MT</given-names></name>. <article-title>AllerHunter: a SVM-pairwise system for assessment of allergenicity and allergic cross-reactivity in proteins</article-title>. <source>PLoS One</source>. <year>2009</year>;<volume>4</volume>(<issue>6</issue>):<fpage>e5861</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0005861</pub-id><pub-id pub-id-type="pmid">19516900</pub-id></mixed-citation></ref><ref id="pone.0144475.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Bui</surname><given-names>HH</given-names></name>, <name><surname>Sidney</surname><given-names>J</given-names></name>, <name><surname>Dinh</surname><given-names>K</given-names></name>, <name><surname>Southwood</surname><given-names>S</given-names></name>, <name><surname>Newman</surname><given-names>MJ</given-names></name>, <name><surname>Sette</surname><given-names>A</given-names></name>. <article-title>Predicting population coverage of T-cell epitope-based diagnostics and vaccines</article-title>. <source>BMC Bioinformatics</source>. <year>2006</year>;<volume>7</volume>:<fpage>153</fpage><pub-id pub-id-type="pmid">16545123</pub-id></mixed-citation></ref><ref id="pone.0144475.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Le</surname><given-names>TM</given-names></name>, <name><surname>Wong</surname><given-names>HH</given-names></name>, <name><surname>Tay</surname><given-names>FP</given-names></name>, <name><surname>Fang</surname><given-names>S</given-names></name>, <name><surname>Keng</surname><given-names>CT</given-names></name>, <name><surname>Tan</surname><given-names>YJ</given-names></name>, <etal>et al</etal><article-title>Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus</article-title>. <source>FEBS J</source>. <year>2007</year>;<volume>274</volume>(<issue>16</issue>):<fpage>4211</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="pmid">17645546</pub-id></mixed-citation></ref><ref id="pone.0144475.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>N</given-names></name>, <name><surname>Shi</surname><given-names>X</given-names></name>, <name><surname>Jiang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Tong</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4</article-title>. <source>Cell Res</source>. <year>2013</year>;<volume>23</volume>(<issue>8</issue>):<fpage>986</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2013.92</pub-id><pub-id pub-id-type="pmid">23835475</pub-id></mixed-citation></ref><ref id="pone.0144475.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Zheng</surname><given-names>N</given-names></name>, <name><surname>Xia</surname><given-names>R</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Yin</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Duan</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice</article-title>. <source>Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>36</issue>):<fpage>5001</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.073</pub-id><pub-id pub-id-type="pmid">19523911</pub-id></mixed-citation></ref><ref id="pone.0144475.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>C</given-names></name>, <name><surname>Yao</surname><given-names>K</given-names></name>, <name><surname>Zhou</surname><given-names>F</given-names></name>, <name><surname>Zhu</surname><given-names>M</given-names></name>. <article-title>Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene</article-title>. <source>Cell Mol Immunol</source>. <year>2006</year>;<volume>3</volume>(<issue>6</issue>):<fpage>459</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="pmid">17257500</pub-id></mixed-citation></ref><ref id="pone.0144475.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>H</given-names></name>, <name><surname>Tao</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>. <article-title>Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice</article-title>. <source>Biotechnol Lett</source>. <year>2009</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1685</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1007/s10529-009-0061-y</pub-id><pub-id pub-id-type="pmid">19579009</pub-id></mixed-citation></ref><ref id="pone.0144475.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Dutta</surname><given-names>NK</given-names></name>, <name><surname>Mazumdar</surname><given-names>K</given-names></name>, <name><surname>Lee</surname><given-names>BH</given-names></name>, <name><surname>Baek</surname><given-names>MW</given-names></name>, <name><surname>Kim</surname><given-names>DJ</given-names></name>, <name><surname>Na</surname><given-names>YR</given-names></name>, <etal>et al</etal><article-title>Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine</article-title>. <source>Immunol Lett</source>. <year>2008</year>;<volume>118</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2008.03.003</pub-id><pub-id pub-id-type="pmid">18440652</pub-id></mixed-citation></ref><ref id="pone.0144475.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>SJ</given-names></name>, <name><surname>Leng</surname><given-names>CH</given-names></name>, <name><surname>Lien</surname><given-names>SP</given-names></name>, <name><surname>Chi</surname><given-names>HY</given-names></name>, <name><surname>Huang</surname><given-names>CY</given-names></name>, <name><surname>Lin</surname><given-names>CL</given-names></name>, <etal>et al</etal><article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title>. <source>Vaccine</source>. <year>2006</year>;<volume>24</volume>(<issue>16</issue>):<fpage>3100</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="pmid">16494977</pub-id></mixed-citation></ref><ref id="pone.0144475.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>J</given-names></name>, <name><surname>Huang</surname><given-names>Q</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Lv</surname><given-names>P</given-names></name>, <name><surname>Gao</surname><given-names>XM</given-names></name>. <article-title>Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus</article-title>. <source>J Virol</source>. <year>2007</year>;<volume>81</volume>(<issue>11</issue>):<fpage>6079</fpage>–<lpage>88</lpage>.
<pub-id pub-id-type="pmid">17392374</pub-id></mixed-citation></ref><ref id="pone.0144475.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>M</given-names></name>, <name><surname>Xu</surname><given-names>D</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Shan</surname><given-names>M</given-names></name>, <name><surname>Tang</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>177</volume>(<issue>4</issue>):<fpage>2138</fpage>–<lpage>45</lpage>.
<pub-id pub-id-type="pmid">16887973</pub-id></mixed-citation></ref><ref id="pone.0144475.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>Z</given-names></name>, <name><surname>Zhao</surname><given-names>F</given-names></name>, <name><surname>Shao</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Kong</surname><given-names>X</given-names></name>, <name><surname>Song</surname><given-names>Y</given-names></name>, <etal>et al</etal><article-title>Fine level epitope mapping and conservation analysis of two novel linear B-cell epitopes of the avian infectious bronchitis coronavirus nucleocapsid protein</article-title>. <source>Virus Res</source>. <year>2013</year>;<volume>171</volume>(<issue>1</issue>):<fpage>54</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2012.10.028</pub-id><pub-id pub-id-type="pmid">23123213</pub-id></mixed-citation></ref><ref id="pone.0144475.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>V</given-names></name>, <name><surname>Tabiin</surname><given-names>TM</given-names></name>, <name><surname>Sun</surname><given-names>K</given-names></name>, <name><surname>Chandrasekaran</surname><given-names>A</given-names></name>, <name><surname>Anwar</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens</article-title>. <source>Virology</source>. <year>2006</year>;<volume>347</volume>(<issue>1</issue>):<fpage>127</fpage>–<lpage>39</lpage>.
<pub-id pub-id-type="pmid">16387339</pub-id></mixed-citation></ref><ref id="pone.0144475.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>DQ</given-names></name>, <name><surname>Ge</surname><given-names>JW</given-names></name>, <name><surname>Qiao</surname><given-names>XY</given-names></name>, <name><surname>Jiang</surname><given-names>YP</given-names></name>, <name><surname>Liu</surname><given-names>SM</given-names></name>, <name><surname>Li</surname><given-names>YJ</given-names></name>. <article-title>High-level mucosal and systemic immune responses induced by oral administration with Lactobacillus-expressed porcine epidemic diarrhea virus (PEDV) S1 region combined with Lactobacillus-expressed N protein</article-title>. <source>Appl Microbiol Biotechnol</source>. <year>2012</year>;<volume>93</volume>(<issue>6</issue>):<fpage>2437</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-011-3734-0</pub-id><pub-id pub-id-type="pmid">22134641</pub-id></mixed-citation></ref><ref id="pone.0144475.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>JA</given-names></name>, <name><surname>Hart</surname><given-names>MK</given-names></name>. <article-title>Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein</article-title>. <source>J Virol</source>. <year>2001</year>;<volume>75</volume>(<issue>6</issue>):<fpage>2660</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="pmid">11222689</pub-id></mixed-citation></ref><ref id="pone.0144475.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>X</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <name><surname>Wu</surname><given-names>C</given-names></name>, <name><surname>Xiao</surname><given-names>Y</given-names></name>, <name><surname>Ren</surname><given-names>L</given-names></name>, <name><surname>Paranhos-Baccalà</surname><given-names>G</given-names></name>, <etal>et al</etal><article-title>Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection</article-title>. <source>J Infect</source>. <year>2015</year>;<volume>71</volume>(<issue>5</issue>):<fpage>599</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2015.07.002</pub-id><pub-id pub-id-type="pmid">26165609</pub-id></mixed-citation></ref><ref id="pone.0144475.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Esser</surname><given-names>MT</given-names></name>, <name><surname>Marchese</surname><given-names>RD</given-names></name>, <name><surname>Kierstead</surname><given-names>LS</given-names></name>, <name><surname>Tussey</surname><given-names>LG</given-names></name>, <name><surname>Wang</surname><given-names>F</given-names></name>, <name><surname>Chirmule</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>Memory T cells and vaccines</article-title>. <source>Vaccine</source>. <year>2003</year>;<volume>21</volume>(<issue>5–6</issue>):<fpage>419</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="pmid">12531640</pub-id></mixed-citation></ref><ref id="pone.0144475.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Maenaka</surname><given-names>K</given-names></name>, <name><surname>Jones</surname><given-names>EY</given-names></name>. <article-title>MHC superfamily structure and the immune system</article-title>. <source>Curr Opin Struct Biol</source>. <year>1999</year>;<volume>9</volume>(<issue>6</issue>):<fpage>745</fpage>–<lpage>53</lpage>.
<pub-id pub-id-type="pmid">10607669</pub-id></mixed-citation></ref><ref id="pone.0144475.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Stern</surname><given-names>LJ</given-names></name>, <name><surname>Wiley</surname><given-names>DC</given-names></name>. <article-title>Antigenic peptide binding by class I and class II histocompatibility proteins</article-title>. <source>Structure</source>. <year>1994</year>; <volume>2</volume>(<issue>4</issue>):<fpage>245</fpage>–<lpage>51</lpage>.
<pub-id pub-id-type="pmid">8087551</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001015 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001015 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |